[{"title01":"Acute myeloid leukemia associated RUNX1 variants induce aberrant expression of transcription factor TCF4","title02":"Acute myeloid leukemia associated RUNX1 variants induce aberrant expression of transcription factor TCF4<\/i>","journal":"Leukemia","issue":"2024 Dec 12. doi: 10.1038\/s41375-024-02470-w. Online ahead of print.","author":"Gerritsen M, In 't Hout FEM, Knops R, Mandos BLR, Decker M, Ripperger T, van der Reijden BA, Martens JHA, Jansen JH.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39668235"},{"title01":"Co-targeting of the thymic stromal lymphopoietin receptor to decrease immunotherapeutic resistance in CRLF2-rearranged Ph-like and Down syndrome acute lymphoblastic leukemia","title02":"Co-targeting of the thymic stromal lymphopoietin receptor to decrease immunotherapeutic resistance in CRLF2<\/i>-rearranged Ph-like and Down syndrome acute lymphoblastic leukemia","journal":"Leukemia","issue":"2024 Dec 16. doi: 10.1038\/s41375-024-02493-3. Online ahead of print.","author":"Balestra T, Niswander LM, Bagashev A, Loftus JP, Ross SL, Chen RK, McClellan SM, Junco JJ, B\u00e1rcenas L\u00f3pez DA, Rabin KR, Fry TJ, Tasian SK.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39681640"},{"title01":"Statistical Perspectives and Meta-Analytic Approaches in Surrogate End Point Evaluation for Chronic Lymphocytic Leukemia","title02":"Statistical Perspectives and Meta-Analytic Approaches in Surrogate End Point Evaluation for Chronic Lymphocytic Leukemia","journal":"J Clin Oncol","issue":"2024 Dec 12:JCO2401881. doi: 10.1200\/JCO-24-01881. Online ahead of print.","author":"Roy A, Brander DM, Hill EG, Halabi S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39666937"},{"title01":"Bleximenib, the novel menin-KMT2A inhibitor JNJ-75276617, impairs long-term proliferation and immune evasion in acute myeloid leukemia","title02":"Bleximenib, the novel menin-KMT2A inhibitor JNJ-75276617, impairs long-term proliferation and immune evasion in acute myeloid leukemia","journal":"Haematologica","issue":"2024 Dec 19. doi: 10.3324\/haematol.2024.285616. Online ahead of print.","author":"Hogeling SM, L\u00ea DM, La Rose N, Kwon MC, Wierenga ATJ, Van den Heuvel FAJ, Van den Boom V, Kuchnio A, Philippar U, Huls G, Schuringa JJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39704147"},{"title01":"Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukaemia arising from a prior myeloproliferative neoplasm","title02":"Olutasidenib demonstrates significant clinical activity in mutated IDH1<\/i> acute myeloid leukaemia arising from a prior myeloproliferative neoplasm","journal":"Br J Haematol","issue":"2024 Dec 19. doi: 10.1111\/bjh.19944. Online ahead of print.","author":"De Botton S, R\u00e9cher C, Cortes J, Curti A, Fenaux P, Peterlin P, Pigneux A, Yee K, Wei A, Mims A, Schiller G, Chao MM, Tian H, Watts JM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39701584"},{"title01":"Landscape of somatic mutations and clonal evolution in NUP98-rearranged adult acute myeloid leukaemia","title02":"Landscape of somatic mutations and clonal evolution in NUP98<\/i>-rearranged adult acute myeloid leukaemia","journal":"Br J Haematol","issue":"2024 Dec 19. doi: 10.1111\/bjh.19962. Online ahead of print.","author":"Frerich C, Li P, Raess PW, Dunlap J, Lachowiez C, Solis-Ruiz J, Press R, Long N, Swords RT, Wiszniewska J, Fan G, Xie W.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39701595"},{"title01":"Advancing the outcomes of AML out of antecedent MPN by targeting mutated IDH1","title02":"Advancing the outcomes of AML out of antecedent MPN by targeting mutated IDH1","journal":"Br J Haematol","issue":"2024 Dec 22. doi: 10.1111\/bjh.19959. Online ahead of print.","author":"Pratz KW.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39710967"},{"title01":"The genomic and clinical consequences of replacing procarbazine with dacarbazine in escalated BEACOPP for Hodgkin lymphoma: a retrospective, observational study","title02":"The genomic and clinical consequences of replacing procarbazine with dacarbazine in escalated BEACOPP for Hodgkin lymphoma: a retrospective, observational study","journal":"Lancet Oncol","issue":"2024 Dec 11:S1470-2045(24)00598-9. doi: 10.1016\/S1470-2045(24)00598-9. Online ahead of print.","author":"Santarsieri A, Mitchell E, Pham MH, Sanghvi R, Jablonski J, Lee-Six H, Sturgess K, Brice P, Menne TF, Osborne W, Creasey T, Ardeshna KM, Baxter J, Behan S, Bhuller K, Booth S, Chavda ND, Collins GP, Culligan DJ, Cwynarski K, Davies A, Downing A, Dutton D, Furtado M, Gallop-Evans E, Hodson A, Hopkins D, Hsu H, Iyengar S, Jones SG, Karanth M, Linton KM, Lomas OC, Martinez-Calle N, Mathur A, McKay P, Nagumantry SK, Phillips EH, Phillips N, Rudge JF, Shah NK, Stafford G, Sternberg A, Trickey R, Uttenthal BJ, Wetherall N, Zhang XY, McMillan AK, Coleman N, Stratton MR, Laurenti E, Borchmann P, Borchmann S, Campbell PJ, Rahbari R, Follows GA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39674188"},{"title01":"Hodgkin lymphoma therapy: minimising clinical and biological harms","title02":"Hodgkin lymphoma therapy: minimising clinical and biological harms","journal":"Lancet Oncol","issue":"2024 Dec 11:S1470-2045(24)00655-7. doi: 10.1016\/S1470-2045(24)00655-7. Online ahead of print.","author":"Viviani S, Tarella C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39674190"},{"title01":"Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma","title02":"Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma","journal":"J Clin Oncol","issue":"2024 Dec 19:JCO2401549. doi: 10.1200\/JCO-24-01549. Online ahead of print.","author":"Foss FM, Kim YH, Prince HM, Akilov OE, Querfeld C, Seminario-Vidal L, Fisher DC, Kuzel TM, Yannakou CK, Geskin LJ, Feldman T, Sokol L, Allen PB, Dang NH, Cabanillas F, Wong HK, Ooi CE, Xing D, Sauter N, Singh P, Czuczman M, Duvic M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39700456"},{"title01":"Metabolic profile evolution in relapsed\/refractory B-cell non-Hodgkin lymphoma patients treated with CD19 chimeric antigen receptor T-cell therapy and implications in clinical outcome","title02":"Metabolic profile evolution in relapsed\/refractory B-cell non-Hodgkin lymphoma patients treated with CD19 chimeric antigen receptor T-cell therapy and implications in clinical outcome","journal":"Haematologica","issue":"2024 Dec 19. doi: 10.3324\/haematol.2024.285154. Online ahead of print.","author":"De Matteis S, Del Coco L, De Castro F, Giudetti AM, Casadei B, Iannotta F, De Felice F, Tomassini E, Vaglio F, Naddeo M, Salamon I, Storci G, Laprovitera N, Messelodi D, Bertuccio SN, Tassoni M, Sinigaglia B, Barbato F, Ursi M, Campanini E, Maffini E, Roberto M, Pellegrini C, Dan E, Pirazzini C, Garagnani P, Ferracin M, Zinzani PL, Fanizzi FP, Bonaf\u00e8 M, Bonifazi F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39704157"},{"title01":"Molecular measurable residual disease by immunoglobulin gene rearrangements on circulating tumor DNA predicts outcome in diffuse large B-cell lymphoma","title02":"Molecular measurable residual disease by immunoglobulin gene rearrangements on circulating tumor DNA predicts outcome in diffuse large B-cell lymphoma","journal":"Haematologica","issue":"2024 Dec 19. doi: 10.3324\/haematol.2024.286331. Online ahead of print.","author":"Soscia R, Assanto GM, Starza ID, Moia R, Talotta D, Bellomarino V, Bellissimo T, Antonacci M, Petrucci L, Gaidano G, Guarini A, Martelli M, Di Rocco A, Fo\u00e0 R, Del Giudice I.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39704164"},{"title01":"Brexucabtagene autoleucel in-vivo expansion and BTKi refractoriness have a negative influence on progression-free survival in mantle cell lymphoma: Results from CART-SIE study","title02":"Brexucabtagene autoleucel in-vivo expansion and BTKi refractoriness have a negative influence on progression-free survival in mantle cell lymphoma: Results from CART-SIE study","journal":"Br J Haematol","issue":"2024 Dec 22. doi: 10.1111\/bjh.19961. Online ahead of print.","author":"Stella F, Chiappella A, Magni M, Bonifazi F, De Philippis C, Musso M, Cutini I, Ljevar S, Barbui AM, Farina M, Martino M, Massaia M, Grillo G, Angelillo P, Botto B, Patriarca F, Krampera M, Arcaini L, Tisi MC, Zinzani P, Sor\u00e0 F, Bramanti S, Pennisi M, Carniti C, Corradini P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39710966"},{"title01":"Acalabrutinib in combination with rituximab and lenalidomide in patients with relapsed or refractory follicular lymphoma: Results of the phase 1b open-label study (ACE-LY-003)","title02":"Acalabrutinib in combination with rituximab and lenalidomide in patients with relapsed or refractory follicular lymphoma: Results of the phase 1b open-label study (ACE-LY-003)","journal":"Br J Haematol","issue":"2024 Dec 12. doi: 10.1111\/bjh.19951. Online ahead of print.","author":"Strati P, Agajanian R, Lossos IS, Coleman M, Kridel R, Wood A, Lesley R, Wun CC, Stephens DM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39667721"},{"title01":"Chimeric antigen receptor copies in cell-free DNA predict relapse in aggressive B-cell lymphoma patients treated with CAR T-cell therapy","title02":"Chimeric antigen receptor copies in cell-free DNA predict relapse in aggressive B-cell lymphoma patients treated with CAR T-cell therapy","journal":"Br J Haematol","issue":"2024 Dec 12. doi: 10.1111\/bjh.19916. Online ahead of print.","author":"de la Iglesia-San Sebasti\u00e1n I, L\u00f3pez-Esteban M, Bastos-Oreiro M, Fern\u00e1ndez de C\u00f3rdoba-O\u00f1ate S, Gutierrez M, Carbonell D, Bail\u00e9n R, G\u00f3mez-Centuri\u00f3n I, Fern\u00e1ndez-Caldas P, Castilla L, Anguita J, Kwon M, Garc\u00eda-Sanz R, Bu\u00f1o I, Mart\u00ednez-Laperche C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39668521"},{"title01":"Treating asymptomatic follicular lymphoma: What is the score?","title02":"Treating asymptomatic follicular lymphoma: What is the score?","journal":"Br J Haematol","issue":"2024 Dec 18. doi: 10.1111\/bjh.19949. Online ahead of print.","author":"Zammar G, Cheah CY.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39696797"},{"title01":"Introduction to a review series on high-risk aggressive lymphoma","title02":"Introduction to a review series on high-risk aggressive lymphoma","journal":"Blood","issue":"2024 Dec 19;144(25):2561-2562.","author":"Sehn LH, Hallek M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39699917"},{"title01":"Prominent expansion of EBV+ large B cells obscuring follicular helper T-cell lymphoma","title02":"Prominent expansion of EBV+ large B cells obscuring follicular helper T-cell lymphoma","journal":"Blood","issue":"2024 Dec 19;144(25):2682.","author":"Yenwongfai LN, Francischetti IMB.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39699923"},{"title01":"DLBclass: A Probabilistic Molecular Classifier to Guide Clinical Investigation and Practice in DLBCL","title02":"DLBclass: A Probabilistic Molecular Classifier to Guide Clinical Investigation and Practice in DLBCL","journal":"Blood","issue":"2024 Dec 16:blood.2024025652. doi: 10.1182\/blood.2024025652. Online ahead of print.","author":"Chapuy B, Wood TR, Stewart C, Dunford AJ, Wienand K, Khan SJ, Serin N, Wang M, Calabretta E, Shimono J, Van Seters S, Wiseman S, Belkin S, Heiman DI, Redd RA, Shipp MA, Getz G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39680847"},{"title01":"EXPRESSION OF CONCERN: HSP70 Inhibition Reverses Cell Adhesion Mediated and Acquired Drug Resistance in Multiple Myeloma","title02":"EXPRESSION OF CONCERN: HSP70 Inhibition Reverses Cell Adhesion Mediated and Acquired Drug Resistance in Multiple Myeloma","journal":"Br J Haematol","issue":"2024 Dec 17. doi: 10.1111\/bjh.19955. Online ahead of print.","author":"No authors listed","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39688017"},{"title01":"Heme promotes venetoclax resistance in multiple myeloma through MEK-ERK signaling and purine biosynthesis","title02":"Heme promotes venetoclax resistance in multiple myeloma through MEK-ERK signaling and purine biosynthesis","journal":"Blood","issue":"2024 Dec 18:blood.2024025690. doi: 10.1182\/blood.2024025690. Online ahead of print.","author":"Nair R, Vu A, Freer AK, Bhatia KS, Wang D, Savani MR, Matulis SM, Lonial S, Jaye DL, Boise LH, Seo SY, Corson TW, Nooka AK, Bhatt S, McBrayer SK, Gupta VA, Hu X, Barwick BG, Reddi AR, Shanmugam M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39693611"},{"title01":"Combined liver-kidney transplantation: 40 years of saving lives","title02":"Combined liver-kidney transplantation: 40 years of saving lives","journal":"Lancet","issue":"2025 Dec 21;404(10471):2538-2539.","author":"Sun X, Kuang X, Wen N, Lei Z, Lan L, Wu J, Mo K, Niu X.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39709199"},{"title01":"Reply to: Human Leukocyte Antigen Mismatching and the Role of Killer Cell Immunoglobulin-Like Receptor Mismatch in Hematopoietic Cell Transplantation for Hematologic Malignancies","title02":"Reply to: Human Leukocyte Antigen Mismatching and the Role of Killer Cell Immunoglobulin-Like Receptor Mismatch in Hematopoietic Cell Transplantation for Hematologic Malignancies","journal":"J Clin Oncol","issue":"2024 Dec 19:JCO2402388. doi: 10.1200\/JCO-24-02388. Online ahead of print.","author":"Arrieta-Bola\u00f1os E, Bonneville EF, Ruggeri A, Fleischhauer K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39700452"},{"title01":"Human Leukocyte Antigen Mismatching and the Role of Killer Cell Immunoglobulin-Like Receptor Mismatch in Hematopoietic Cell Transplantation for Hematologic Malignancies","title02":"Human Leukocyte Antigen Mismatching and the Role of Killer Cell Immunoglobulin-Like Receptor Mismatch in Hematopoietic Cell Transplantation for Hematologic Malignancies","journal":"J Clin Oncol","issue":"2024 Dec 19:JCO2401869. doi: 10.1200\/JCO-24-01869. Online ahead of print.","author":"Shimazu Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39700453"},{"title01":"Humanized anti-CD25 monoclonal antibody replaces methotrexate as acute graft-versus-host disease prophylaxis in haploidentical allogeneic haematopoietic stem cell transplantation","title02":"Humanized anti-CD25 monoclonal antibody replaces methotrexate as acute graft-versus-host disease prophylaxis in haploidentical allogeneic haematopoietic stem cell transplantation","journal":"Br J Haematol","issue":"2024 Dec 22. doi: 10.1111\/bjh.19958. Online ahead of print.","author":"Zhang A, Huang Z, Zhang R, Wei R, Jiang S, Chen H, Cao X, Shi W, Xia L, Hu Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39710371"},{"title01":"Increasing the dose of recombinant human thrombopoietin can enhance platelet engraftment after allogeneic haematopoietic stem cell transplantation: A NICHE cohort study","title02":"Increasing the dose of recombinant human thrombopoietin can enhance platelet engraftment after allogeneic haematopoietic stem cell transplantation: A NICHE cohort study","journal":"Br J Haematol","issue":"2024 Dec 15. doi: 10.1111\/bjh.19954. Online ahead of print.","author":"Feng D, Liu Q, Gao H, Cao Y, Chen X, Zhang R, Zhai W, Yang D, Wei J, He Y, Pang A, Feng S, Han M, Ma Q, Jiang E.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39676311"},{"title01":"How to make transplanted stem cells feel at home","title02":"How to make transplanted stem cells feel at home","journal":"Blood","issue":"2024 Dec 19;144(25):2564-2566.","author":"Machowicz R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39699920"},{"title01":"Oral Inflammation and Microbiome Dysbiosis Exacerbate Chronic Graft-versus-host Disease","title02":"Oral Inflammation and Microbiome Dysbiosis Exacerbate Chronic Graft-versus-host Disease","journal":"Blood","issue":"2024 Dec 18:blood.2024024540. doi: 10.1182\/blood.2024024540. Online ahead of print.","author":"Kambara Y, Fujiwara H, Yamamoto A, Gotoh K, Tsuji S, Kunihiro M, Oyama T, Terao T, Sato A, Tanaka T, Peltier D, Seike K, Nishimori H, Asada N, Ennishi D, Fujii K, Fujii N, Matsuoka KI, Soga Y, Reddy P, Maeda Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39693612"},{"title01":"Reply to: Human Leukocyte Antigen Mismatching and the Role of Killer Cell Immunoglobulin-Like Receptor Mismatch in Hematopoietic Cell Transplantation for Hematologic Malignancies","title02":"Reply to: Human Leukocyte Antigen Mismatching and the Role of Killer Cell Immunoglobulin-Like Receptor Mismatch in Hematopoietic Cell Transplantation for Hematologic Malignancies","journal":"J Clin Oncol","issue":"2024 Dec 19:JCO2402388. doi: 10.1200\/JCO-24-02388. Online ahead of print.","author":"Arrieta-Bola\u00f1os E, Bonneville EF, Ruggeri A, Fleischhauer K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39700452"},{"title01":"Human Leukocyte Antigen Mismatching and the Role of Killer Cell Immunoglobulin-Like Receptor Mismatch in Hematopoietic Cell Transplantation for Hematologic Malignancies","title02":"Human Leukocyte Antigen Mismatching and the Role of Killer Cell Immunoglobulin-Like Receptor Mismatch in Hematopoietic Cell Transplantation for Hematologic Malignancies","journal":"J Clin Oncol","issue":"2024 Dec 19:JCO2401869. doi: 10.1200\/JCO-24-01869. Online ahead of print.","author":"Shimazu Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39700453"},{"title01":"Humanized anti-CD25 monoclonal antibody replaces methotrexate as acute graft-versus-host disease prophylaxis in haploidentical allogeneic haematopoietic stem cell transplantation","title02":"Humanized anti-CD25 monoclonal antibody replaces methotrexate as acute graft-versus-host disease prophylaxis in haploidentical allogeneic haematopoietic stem cell transplantation","journal":"Br J Haematol","issue":"2024 Dec 22. doi: 10.1111\/bjh.19958. Online ahead of print.","author":"Zhang A, Huang Z, Zhang R, Wei R, Jiang S, Chen H, Cao X, Shi W, Xia L, Hu Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39710371"},{"title01":"Reframing thalassaemia syndrome as a benign haematopoietic stem cell disorder","title02":"Reframing thalassaemia syndrome as a benign haematopoietic stem cell disorder","journal":"Br J Haematol","issue":"2024 Dec 15. doi: 10.1111\/bjh.19919. Online ahead of print.","author":"Maggio A, Napolitano M, Taher AT, Bou-Fakhredin R, Ostuni MA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39676308"},{"title01":"Increasing the dose of recombinant human thrombopoietin can enhance platelet engraftment after allogeneic haematopoietic stem cell transplantation: A NICHE cohort study","title02":"Increasing the dose of recombinant human thrombopoietin can enhance platelet engraftment after allogeneic haematopoietic stem cell transplantation: A NICHE cohort study","journal":"Br J Haematol","issue":"2024 Dec 15. doi: 10.1111\/bjh.19954. Online ahead of print.","author":"Feng D, Liu Q, Gao H, Cao Y, Chen X, Zhang R, Zhai W, Yang D, Wei J, He Y, Pang A, Feng S, Han M, Ma Q, Jiang E.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39676311"},{"title01":"How to make transplanted stem cells feel at home","title02":"How to make transplanted stem cells feel at home","journal":"Blood","issue":"2024 Dec 19;144(25):2564-2566.","author":"Machowicz R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39699920"},{"title01":"How I Treat AML relapse after allogeneic HCT","title02":"How I Treat AML relapse after allogeneic HCT","journal":"Blood","issue":"2024 Dec 24:blood.2024025705. doi: 10.1182\/blood.2024025705. Online ahead of print.","author":"Gooptu M, Murdock HM, Soiffer RJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39719042"},{"title01":"Sickle cell anaemia therapy in 2025","title02":"Sickle cell anaemia therapy in 2025","journal":"Br J Haematol","issue":"2024 Dec 22. doi: 10.1111\/bjh.19933. Online ahead of print.","author":"Schechter AN.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39710962"},{"title01":"Corticosteroids plus metformin versus corticosteroids as front-line treatment for patients with newly diagnosed ITP and pre-existing type 2 diabetes mellitus: A multicentre propensity score-matched study","title02":"Corticosteroids plus metformin versus corticosteroids as front-line treatment for patients with newly diagnosed ITP and pre-existing type 2 diabetes mellitus: A multicentre propensity score-matched study","journal":"Br J Haematol","issue":"2024 Dec 18. doi: 10.1111\/bjh.19940. Online ahead of print.","author":"Hou XR, Yan ZY, Liu S, Gao N, Chen J, Wang YW, Wang L, Li Z, Wang XR, Dong QF, Wang QY, Sun L, Wang YM, Ma J, Zhao YJ, Xu ZL, Cao CC, Peng J, Hou M, Liu XG.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39696781"},{"title01":"Asciminib in Newly Diagnosed Chronic Myeloid Leukemia","title02":"Asciminib in Newly Diagnosed Chronic Myeloid Leukemia","journal":"N Engl J Med","issue":"2024 Dec 12;391(23):2274-2275.","author":"Gambacorti-Passerini C, Piazza R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39665662"},{"title01":"Asciminib in Newly Diagnosed Chronic Myeloid Leukemia","title02":"Asciminib in Newly Diagnosed Chronic Myeloid Leukemia","journal":"N Engl J Med","issue":"2024 Dec 12;391(23):2275.","author":"Punwani N.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39665663"},{"title01":"Asciminib in Newly Diagnosed Chronic Myeloid Leukemia. Reply","title02":"Asciminib in Newly Diagnosed Chronic Myeloid Leukemia. Reply","journal":"N Engl J Med","issue":"2024 Dec 12;391(23):2275-2276.","author":"Hochhaus A, Cortes JE, Hughes TP.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39665664"},{"title01":"Asciminib in Newly Diagnosed Chronic Myeloid Leukemia. Reply","title02":"Asciminib in Newly Diagnosed Chronic Myeloid Leukemia. Reply","journal":"N Engl J Med","issue":"2024 Dec 12;391(23):2276.","author":"Abruzzese E.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39665665"},{"title01":"Hairy-Cell Leukemia","title02":"Hairy-Cell Leukemia","journal":"N Engl J Med","issue":"2024 Dec 19;391(24):2386-2387.","author":"Reinhold I, Cornely OA, Stemler J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39693558"},{"title01":"Hairy-Cell Leukemia","title02":"Hairy-Cell Leukemia","journal":"N Engl J Med","issue":"2024 Dec 19;391(24):2387-2388.","author":"Hermel DJ, Saven A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39693559"},{"title01":"Hairy-Cell Leukemia. Reply","title02":"Hairy-Cell Leukemia. Reply","journal":"N Engl J Med","issue":"2024 Dec 19;391(24):2388.","author":"Falini B, Tiacci E.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39693560"},{"title01":"ADAR1 is required for acute myeloid leukemia cell survival by modulating post-transcriptional Wnt signaling through impairing miRNA biogenesis","title02":"ADAR1 is required for acute myeloid leukemia cell survival by modulating post-transcriptional Wnt signaling through impairing miRNA biogenesis","journal":"Leukemia","issue":"2024 Dec 19. doi: 10.1038\/s41375-024-02500-7. Online ahead of print.","author":"Shi Z, Li J, Ding J, Zhang Y, Min W, Zhu Y, Hou Y, Yuan K, Sun C, Wang X, Shen H, Wang L, Liang SQ, Kuang W, Wang X, Yang P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39702795"},{"title01":"Relationship between donor source, pre-transplant measurable residual disease, and outcome after allografting for adults with acute myeloid leukemia","title02":"Relationship between donor source, pre-transplant measurable residual disease, and outcome after allografting for adults with acute myeloid leukemia","journal":"Leukemia","issue":"2024 Dec 12. doi: 10.1038\/s41375-024-02497-z. Online ahead of print.","author":"Orvain C, Milano F, Rodr\u00edguez-Arbol\u00ed E, Othus M, Petersdorf EW, Sandmaier BM, Appelbaum FR, Walter RB.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39668236"},{"title01":"Immunoglobulin light chain mutational status refines IGHV prognostic value in identifying chronic lymphocytic leukemia patients with early treatment requirement","title02":"Immunoglobulin light chain mutational status refines IGHV prognostic value in identifying chronic lymphocytic leukemia patients with early treatment requirement","journal":"Leukemia","issue":"2024 Dec 17. doi: 10.1038\/s41375-024-02499-x. Online ahead of print.","author":"Nabki J, Al Deeban B, Sium AM, Cosentino C, Almasri M, Awikeh B, Maher N, Bellia M, Dondolin R, Mouhssine S, Talotta D, Secomandi E, Kogila S, Ghanej J, Maiellaro F, Cividini L, Rasi S, Chiarenza A, Olivieri J, Gentile M, Zaja F, Del Principe MI, Laurenti L, Bomben R, Vit F, Bittolo T, Zucchetto A, Gattei V, Gaidano G, Moia R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39690182"},{"title01":"CPX-351 +\/- gemtuzumab ozogamicin as induction therapy for adult patients with newly diagnosed, favourable-intermediate risk, FLT3-ITD negative, AML: A pilot study","title02":"CPX-351 +\/- gemtuzumab ozogamicin as induction therapy for adult patients with newly diagnosed, favourable-intermediate risk, FLT3-ITD negative, AML: A pilot study","journal":"Br J Haematol","issue":"2024 Dec 25. doi: 10.1111\/bjh.19967. Online ahead of print.","author":"Ganzel C, Frisch A, Wolach O, Moshe Y, Krayem B, Dor N, Broide E, Benayoun E, Rowe JM, Ofran Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39721590"},{"title01":"Chronic lymphocytic leukaemia with trisomy 12","title02":"Chronic lymphocytic leukaemia with trisomy 12","journal":"Br J Haematol","issue":"2024 Dec 17. doi: 10.1111\/bjh.19946. Online ahead of print.","author":"Quach P, Hogan KO.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39690108"},{"title01":"Non-V600E BRAF mutations and treatment for Hairy Cell Leukemia","title02":"Non-V600E BRAF mutations and treatment for Hairy Cell Leukemia","journal":"Blood","issue":"2024 Dec 24:blood.2024026894. doi: 10.1182\/blood.2024026894. Online ahead of print.","author":"Arons E, Tai CH, Suraj J, Liu Y, Day CP, Raffeld M, Xi L, Gould M, Shpilman ID, Oakes CC, Bhat SA, Grever MR, Jones D, Rogers KA, Wang HW, Yuan CM, Sahinalp SC, Kreitman RJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39719040"},{"title01":"Menin inhibitors in the treatment of acute myeloid leukemia","title02":"Menin inhibitors in the treatment of acute myeloid leukemia","journal":"Blood","issue":"2024 Dec 24:blood.2024026232. doi: 10.1182\/blood.2024026232. Online ahead of print.","author":"Huls GA, Woolthuis CM, Schuringa JJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39719041"},{"title01":"How I Treat AML relapse after allogeneic HCT","title02":"How I Treat AML relapse after allogeneic HCT","journal":"Blood","issue":"2024 Dec 24:blood.2024025705. doi: 10.1182\/blood.2024025705. Online ahead of print.","author":"Gooptu M, Murdock HM, Soiffer RJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39719042"},{"title01":"Progressive chromatin rewiring by ETO2::GLIS2 revealed in a human iPSC model of pediatric leukemia initiation","title02":"Progressive chromatin rewiring by ETO2::GLIS2 revealed in a human iPSC model of pediatric leukemia initiation","journal":"Blood","issue":"2024 Dec 10:blood.2024024505. doi: 10.1182\/blood.2024024505. Online ahead of print.","author":"Boudia F, Baille M, Babin L, Aid Z, Robert E, Riviere J, Galant K, Alonso-P\u00e9rez V, Anselmi L, Arkoun B, Abermil N, Marzac C, Bertuccio SN, Regnault de Premesnil A, Lopez CK, Eeckhoutte A, Naimo A, Leite B, Catelain C, Metereau C, Gonin P, Gaspar N, Schwaller J, Bernard OA, Raslova H, Gaudry M, Marchais A, Lapillonne H, Petit A, Pflumio F, Arcangeli ML, Brunet E, Mercher T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39656971"},{"title01":"Genetic susceptibility of diffuse large B-cell lymphoma: a meta genome-wide association study in Asian population","title02":"Genetic susceptibility of diffuse large B-cell lymphoma: a meta genome-wide association study in Asian population","journal":"Leukemia","issue":"2024 Dec 20. doi: 10.1038\/s41375-024-02503-4. Online ahead of print.","author":"Cui Q, Tan W, Song B, Peng RJ, Wang L, Dorajoo R, Ng KP, Lin GW, Au WY, Liang RHS, Khor CC, Zhang QL, Foo JN, Li SP, Zhang FR, Zhang XJ, Yu XQ, Lan Q, Chanock S, Jia WH, Lim ST, Li WY, Rothman N, Bei JX, Liu J, Lin D, Liu JJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39707004"},{"title01":"T-cell diversity and exclusion of blood-derived T-cells in the tumor microenvironment of classical Hodgkin Lymphoma","title02":"T-cell diversity and exclusion of blood-derived T-cells in the tumor microenvironment of classical Hodgkin Lymphoma","journal":"Leukemia","issue":"2024 Dec 17. doi: 10.1038\/s41375-024-02490-6. Online ahead of print.","author":"Seifert N, Reinke S, Grund J, M\u00fcller-Meinhard B, Richter J, Heilmann T, Schl\u00f6\u00dfer H, Kotrova M, Br\u00fcggemann M, Borchmann P, Br\u00f6ckelmann PJ, Altenbuchinger M, Klapper W.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39690183"},{"title01":"Letermovir prophylaxis for cytomegalovirus is associated with risk of post-transplant lymphoproliferative disorders after haploidentical stem cell transplantation","title02":"Letermovir prophylaxis for cytomegalovirus is associated with risk of post-transplant lymphoproliferative disorders after haploidentical stem cell transplantation","journal":"Haematologica","issue":"2024 Nov 28. doi: 10.3324\/haematol.2024.286265. Online ahead of print.","author":"Pei XY, Huang Q, Luo LJ, Sun HL, Liu J, Sun YQ, Mo XD, Lv M, Liu DH, Ma HY, Wu YW, Xu LP, Wang Y, Zhang XH, Chen L, Huang XJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39605206"},{"title01":"Intestinal perforation following allogeneic stem cell transplantation caused by Epstein-Barr virus-positive mucocutaneous ulcer","title02":"Intestinal perforation following allogeneic stem cell transplantation caused by Epstein-Barr virus-positive mucocutaneous ulcer","journal":"Haematologica","issue":"2024 Dec 5. doi: 10.3324\/haematol.2024.286488. Online ahead of print.","author":"Hirschb\u00fchl K, Schaller T, M\u00e4rkl B, Amerein A, Gebhard M, Braun G, Wasserberg S, Sala E, Trepel M, Schmid C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39633546"},{"title01":"Does size matter? Center-specific characteristics and survival after allogeneic hematopoietic cell transplantation for acute myeloid leukemia: an analysis of the German Registry for Stem Cell Transplantation and Cell Therapy","title02":"Does size matter? Center-specific characteristics and survival after allogeneic hematopoietic cell transplantation for acute myeloid leukemia: an analysis of the German Registry for Stem Cell Transplantation and Cell Therapy","journal":"Haematologica","issue":"2024 Dec 5. doi: 10.3324\/haematol.2024.286385. Online ahead of print.","author":"Bethge W, Flossdorf S, Hanke F, Schmid C, Ringhoffer M, Klein S, Hertenstein B, Schetelig J, Stelljes M, Schroeder T, Blau IW, Ayuk F, Eder M, Zeiser R, Fleischhauer K, Kr\u00f6ger N, Dreger P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39633549"},{"title01":"Evolution of myeloproliferative neoplasms from normal blood stem cells","title02":"Evolution of myeloproliferative neoplasms from normal blood stem cells","journal":"Haematologica","issue":"2024 Dec 5. doi: 10.3324\/haematol.2023.283951. Online ahead of print.","author":"Hormoz S, Sankaran VG, Mullally A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39633553"},{"title01":"Haematopoietic gene therapy of non-conditioned patients with Fanconi anaemia-A: results from open-label phase 1\/2 (FANCOLEN-1) and long-term clinical trials","title02":"Haematopoietic gene therapy of non-conditioned patients with Fanconi anaemia-A: results from open-label phase 1\/2 (FANCOLEN-1) and long-term clinical trials","journal":"Lancet","issue":"2024 Dec 3:S0140-6736(24)01880-4. doi: 10.1016\/S0140-6736(24)01880-4. Online ahead of print.","author":"R\u00edo P, Zubicaray J, Navarro S, G\u00e1lvez E, S\u00e1nchez-Dom\u00ednguez R, Nicoletti E, Sebasti\u00e1n E, Rothe M, Pujol R, Bogliolo M, John-Neek P, Bastone AL, Schambach A, Wang W, Schmidt M, Larcher L, Segovia JC, Y\u00e1\u00f1ez RM, Alberquilla O, D\u00edez B, Fern\u00e1ndez-Garc\u00eda M, Garc\u00eda-Garc\u00eda L, Ram\u00edrez M, Galy A, Lefrere F, Cavazzana M, Leblanc T, Garc\u00eda de Andoin N, L\u00f3pez-Almaraz R, Catal\u00e1 A, Barquinero J, Rodr\u00edguez-Perales S, Rao G, Surrall\u00e9s J, Soulier J, D\u00edaz-de-Heredia C, Schwartz JD, Sevilla J, Bueren JA; FANCOLEN-1 gene therapy investigators.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39642902"},{"title01":"Reduced GATA1 levels are associated with ineffective erythropoiesis in sickle cell anemia","title02":"Reduced GATA1 levels are associated with ineffective erythropoiesis in sickle cell anemia","journal":"Haematologica","issue":"2024 Dec 5. doi: 10.3324\/haematol.2024.286010. Online ahead of print.","author":"El Hoss S, Shangaris P, Brewin J, Psychogyiou ME, Ng C, Pedler L, Rooks H, Gotardo \u00c9MF, Gushiken LFS, Brito PL, Nicolaides KH, Conran N, Rees DC, Strouboulis J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39633531"},{"title01":"Elucidating loss-of-function mechanisms of monoallelic EPAS1 mutations underlying congenital hypoplastic anaemia in a paediatric anaemia cohort","title02":"Elucidating loss-of-function mechanisms of monoallelic EPAS1<\/i> mutations underlying congenital hypoplastic anaemia in a paediatric anaemia cohort","journal":"Br J Haematol","issue":"2024 Nov 29. doi: 10.1111\/bjh.19930. Online ahead of print.","author":"Zhang J, Sun J, Huai W, Tang J, Chen J, Yao R, Yu T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39613395"},{"title01":"\u03b2-Thalassemia minor is associated with high rates of worsening anemia in pregnancy","title02":"\u03b2-Thalassemia minor is associated with high rates of worsening anemia in pregnancy","journal":"Blood","issue":"2024 Dec 9:blood.2024026736. doi: 10.1182\/blood.2024026736. Online ahead of print.","author":"Langer AL, Goggins BB, Esrick EB, Fell G, Berliner N, Economy KE.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39652827"},{"title01":"An erythroid-specific lentiviral vector improves anemia and iron metabolism in a new model of XLSA","title02":"An erythroid-specific lentiviral vector improves anemia and iron metabolism in a new model of XLSA","journal":"Blood","issue":"2024 Dec 10:blood.2024025846. doi: 10.1182\/blood.2024025846. Online ahead of print.","author":"Castruccio Castracani C, Breda L, Papp TE, Guerra A, Radaelli E, Assenmacher CA, Finesso G, Mui BL, Tam YK, Fontana S, Riganti C, Fiorito V, Petrillo S, Tolosano E, Parhiz H, Rivella S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39656107"},{"title01":"Air pollution, residential greenspace, and the risk of incident immune thrombocytopenic purpura: a prospective cohort study of 356,482 participants","title02":"Air pollution, residential greenspace, and the risk of incident immune thrombocytopenic purpura: a prospective cohort study of 356,482 participants","journal":"Haematologica","issue":"2024 Dec 5. doi: 10.3324\/haematol.2024.286328. Online ahead of print.","author":"Luo P, Wang F, Ying J, Liu K, Hua B, Chen S, Li J, Sun X, Ye D, Ye B, Tong J, Shao K, Mao Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39633544"},{"title01":"Allogeneic hematopoietic stem cell transplantation in adult acute myeloid leukemia with t(16;21)(p11;q22)\/FUS::ERG","title02":"Allogeneic hematopoietic stem cell transplantation in adult acute myeloid leukemia with t(16;21)(p11;q22)\/FUS::ERG<\/i>","journal":"Leukemia","issue":"2024 Dec 10. doi: 10.1038\/s41375-024-02495-1. Online ahead of print.","author":"Mitsuyuki S, Shimomura Y, Mizumaki H, Yanada M, Mizuno S, Uchida N, Doki N, Ito A, Tanaka M, Nishida T, Katayama Y, Yoshihara S, Eto T, Takada S, Ota S, Toyosaki M, Hasegawa Y, Nakamae H, Kawamura K, Onizuka M, Fukuda T, Ohbiki M, Atsuta Y, Konuma T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39658629"},{"title01":"Influence of Nucleophosmin (NPM1) Genotypes on Outcome of Patients With AML: An AIEOP-BFM and COG-SWOG Intergroup Collaboration","title02":"Influence of Nucleophosmin (NPM1<\/i>) Genotypes on Outcome of Patients With AML: An AIEOP-BFM and COG-SWOG Intergroup Collaboration","journal":"J Clin Oncol","issue":"2024 Dec 2:JCO2401715. doi: 10.1200\/JCO-24-01715. Online ahead of print.","author":"Tregnago C, Benetton M, Ries RE, Peplinski JH, Alonzo TA, Stirewalt D, Othus M, Duployez N, Sonneveld E, Abrahamsson J, Fogelstrand L, von Neuhoff N, Hasle H, Reinhardt D, Meshinchi S, Locatelli F, Pigazzi M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39621969"},{"title01":"Allogeneic hematopoietic stem cell transplantation in adult acute myeloid leukemia with t(16;21)(p11;q22)\/FUS::ERG","title02":"Allogeneic hematopoietic stem cell transplantation in adult acute myeloid leukemia with t(16;21)(p11;q22)\/FUS::ERG<\/i>","journal":"Leukemia","issue":"2024 Dec 10. doi: 10.1038\/s41375-024-02495-1. Online ahead of print.","author":"Mitsuyuki S, Shimomura Y, Mizumaki H, Yanada M, Mizuno S, Uchida N, Doki N, Ito A, Tanaka M, Nishida T, Katayama Y, Yoshihara S, Eto T, Takada S, Ota S, Toyosaki M, Hasegawa Y, Nakamae H, Kawamura K, Onizuka M, Fukuda T, Ohbiki M, Atsuta Y, Konuma T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39658629"},{"title01":"Autologous stem cell transplantation for multiple myeloma patients whose myeloma-defining event was SLiM","title02":"Autologous stem cell transplantation for multiple myeloma patients whose myeloma-defining event was SLiM","journal":"Br J Haematol","issue":"2024 Nov 29. doi: 10.1111\/bjh.19936. Online ahead of print.","author":"Vaxman I, Kumar S, Cohen I, Simony S, Dispenzieri A, Buadi F, Dingli D, Muchtar E, Kapoor P, Hogan W, Hayman S, Leung N, Gonsalves W, Kourelis T, Warsame R, Gertz M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39613336"},{"title01":"Clinical perspectives on post-induction maintenance therapy in patients with acute myeloid leukaemia in remission who are ineligible for allogeneic haematopoietic stem cell transplantation","title02":"Clinical perspectives on post-induction maintenance therapy in patients with acute myeloid leukaemia in remission who are ineligible for allogeneic haematopoietic stem cell transplantation","journal":"Br J Haematol","issue":"2024 Dec 2. doi: 10.1111\/bjh.19924. Online ahead of print.","author":"Sweet K, Cluzeau T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39622271"},{"title01":"Can JAK inhibition prevent GVHD?","title02":"Can JAK inhibition prevent GVHD?","journal":"Blood","issue":"2024 Nov 28;144(22):2273-2274.","author":"DeFilipp Z.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39607712"},{"title01":"Lentiviral Gene Therapy with CD34+ Hematopoietic Cells for Hemophilia A","title02":"Lentiviral Gene Therapy with CD34+ Hematopoietic Cells for Hemophilia A","journal":"N Engl J Med","issue":"2024 Dec 9. doi: 10.1056\/NEJMoa2410597. Online ahead of print.","author":"Srivastava A, Abraham A, Aboobacker F, Singh G, Geevar T, Kulkarni U, Selvarajan S, Korula A, Dave RG, Shankar M, Singh AS, Jeba A, Kumaar N, Benjamin C, Lakshmi KM, Srivastava VM, Shaji RV, Nair SC, Brown HC, Denning G, Lollar P, Doering CB, Spencer T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39655790"},{"title01":"Allogeneic hematopoietic stem cell transplantation in adult acute myeloid leukemia with t(16;21)(p11;q22)\/FUS::ERG","title02":"Allogeneic hematopoietic stem cell transplantation in adult acute myeloid leukemia with t(16;21)(p11;q22)\/FUS::ERG<\/i>","journal":"Leukemia","issue":"2024 Dec 10. doi: 10.1038\/s41375-024-02495-1. Online ahead of print.","author":"Mitsuyuki S, Shimomura Y, Mizumaki H, Yanada M, Mizuno S, Uchida N, Doki N, Ito A, Tanaka M, Nishida T, Katayama Y, Yoshihara S, Eto T, Takada S, Ota S, Toyosaki M, Hasegawa Y, Nakamae H, Kawamura K, Onizuka M, Fukuda T, Ohbiki M, Atsuta Y, Konuma T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39658629"},{"title01":"Everyone is a potential lifesaving stem cell donor","title02":"Everyone is a potential lifesaving stem cell donor","journal":"Lancet Haematol","issue":"2024 Dec;11(12):e879.","author":"The Lancet Haematology.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39638535"},{"title01":"The impact of patient ethnicity on haematopoietic cell transplantation outcome: a retrospective cohort study on the UK experience","title02":"The impact of patient ethnicity on haematopoietic cell transplantation outcome: a retrospective cohort study on the UK experience","journal":"Lancet Haematol","issue":"2024 Dec;11(12):e916-e926.","author":"Mayor NP, Szydlo RM, Sheikh Y, Lee J, Pearce RM, Farrow C, Agapiou M, Rao K, Orchard K, Olavarria E, Marsh SGE, Snowden JA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39638542"},{"title01":"Donor cytomegalovirus serology impacts overall survival in children receiving first unrelated hematopoietic stem cell transplant for acute leukemia: European Society of Bone Marrow Transplantation Pediatric Diseases Working Party Study","title02":"Donor cytomegalovirus serology impacts overall survival in children receiving first unrelated hematopoietic stem cell transplant for acute leukemia: European Society of Bone Marrow Transplantation Pediatric Diseases Working Party Study","journal":"Haematologica","issue":"2024 Nov 28. doi: 10.3324\/haematol.2024.286082. Online ahead of print.","author":"Ince E, Galimard JE, Ifversen M, Dalissier A, Szmit Z, Mirci-Danicar O, Locatelli F, Sedlacek P, Styczynski J, Dalle JH, Renard C, Balduzzi A, Lankester A, Bierings M, Fagioli F, Kielsen K, Rialland F, B\u00fcchner J, Taskinen M, Wynn R, Jubert C, Michel G, Pichler H, Krivan G, Cesaro S, Corbacioglu S, Meisel R, Kalwak K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39605204"},{"title01":"Impact of body mass index on outcomes of multiple myeloma patients undergoing upfront autologous stem cell transplant","title02":"Impact of body mass index on outcomes of multiple myeloma patients undergoing upfront autologous stem cell transplant","journal":"Br J Haematol","issue":"2024 Nov 28. doi: 10.1111\/bjh.19937. Online ahead of print.","author":"Marcoux C, Pasyar S, Milton DR, Khan HN, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Neupane N, Lee HC, Patel KK, Tang G, Aljawai Y, Kebriaei P, Thomas SK, Orlowski RZ, Shpall EJ, Champlin R, Qazilbash MH, Pasvolsky O.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39610225"},{"title01":"Autologous stem cell transplantation for multiple myeloma patients whose myeloma-defining event was SLiM","title02":"Autologous stem cell transplantation for multiple myeloma patients whose myeloma-defining event was SLiM","journal":"Br J Haematol","issue":"2024 Nov 29. doi: 10.1111\/bjh.19936. Online ahead of print.","author":"Vaxman I, Kumar S, Cohen I, Simony S, Dispenzieri A, Buadi F, Dingli D, Muchtar E, Kapoor P, Hogan W, Hayman S, Leung N, Gonsalves W, Kourelis T, Warsame R, Gertz M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39613336"},{"title01":"Clinical perspectives on post-induction maintenance therapy in patients with acute myeloid leukaemia in remission who are ineligible for allogeneic haematopoietic stem cell transplantation","title02":"Clinical perspectives on post-induction maintenance therapy in patients with acute myeloid leukaemia in remission who are ineligible for allogeneic haematopoietic stem cell transplantation","journal":"Br J Haematol","issue":"2024 Dec 2. doi: 10.1111\/bjh.19924. Online ahead of print.","author":"Sweet K, Cluzeau T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39622271"},{"title01":"Incidence of Richter transformation of chronic lymphocytic leukemia\/small lymphocytic lymphoma in the targeted therapy era","title02":"Incidence of Richter transformation of chronic lymphocytic leukemia\/small lymphocytic lymphoma in the targeted therapy era","journal":"Leukemia","issue":"2024 Dec 10. doi: 10.1038\/s41375-024-02492-4. Online ahead of print.","author":"Hampel PJ, Rabe KG, Wang Y, Hwang SR, Kenderian SS, Muchtar E, Leis JF, Koehler AB, Tsang M, Hilal T, Parrondo R, Bailen RJ, Schwager SM, Hanson CA, Braggio E, Slager SL, Shi M, Zepeda-Mendoza CJ, Van Dyke DL, Shanafelt TD, King RL, Call TG, Kay NE, Ding W, Parikh SA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39658628"},{"title01":"Growth retardation and adult height in pediatric patients with chronic-phase chronic myeloid leukemia treated with tyrosine kinase inhibitors","title02":"Growth retardation and adult height in pediatric patients with chronic-phase chronic myeloid leukemia treated with tyrosine kinase inhibitors","journal":"Leukemia","issue":"2024 Dec 12. doi: 10.1038\/s41375-024-02488-0. Online ahead of print.","author":"Shima H, Tono C, Tanizawa A, Ito M, Watanabe A, Yuza Y, Hamamoto K, Muramatsu H, Okada M, Saito S, Goto H, Imamura M, Saito AM, Adachi S, Ishii E, Shimada H.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39663405"},{"title01":"Prognostic relevance of treatment deviations in children with relapsed acute lymphoblastic leukemia who were treated in the ALL-REZ BFM 2002 study","title02":"Prognostic relevance of treatment deviations in children with relapsed acute lymphoblastic leukemia who were treated in the ALL-REZ BFM 2002 study","journal":"Leukemia","issue":"2024 Dec 11. doi: 10.1038\/s41375-024-02474-6. Online ahead of print.","author":"Argyriadi EA, Steffen IG, Chen-Santel C, Lissat A, Attarbaschi A, Bourquin JP, Henze G, von Stackelberg A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39663406"},{"title01":"Infection-related pathway activation and vulnerability to arsenic trioxide in acute promyelocytic leukemia with TTMV::RARA","title02":"Infection-related pathway activation and vulnerability to arsenic trioxide in acute promyelocytic leukemia with TTMV::RARA","journal":"Leukemia","issue":"2024 Nov 28. doi: 10.1038\/s41375-024-02481-7. Online ahead of print.","author":"Lou J, Zhang Y, Tao J, Jin W, Zhu Y, Wang Z, Wu M, Yi H, Chen X, Shen S, Li J, Chen Z, Chen S, Xie Y, Chen L, Wang K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39609596"},{"title01":"Is there really an accelerated phase of chronic myeloid leukaemia at presentation?","title02":"Is there really an accelerated phase of chronic myeloid leukaemia at presentation?","journal":"Leukemia","issue":"2024 Dec 4. doi: 10.1038\/s41375-024-02486-2. Online ahead of print.","author":"Yang S, Zhang X, Gale RP, Huang X, Jiang Q.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39633067"},{"title01":"HMX3 is a critical vulnerability in MECOM-negative KMT2A::MLLT3 acute myelomonocytic leukemia","title02":"HMX3 is a critical vulnerability in MECOM-negative KMT2A::MLLT3 acute myelomonocytic leukemia","journal":"Leukemia","issue":"2024 Dec 4. doi: 10.1038\/s41375-024-02485-3. Online ahead of print.","author":"Arza-Apalategi S, Heuts BMH, Bergevoet SM, Meering R, Gilissen D, Jansen PWTC, Krippner-Heidenreich A, Valk PJM, Vermeulen M, Heidenreich O, Haferlach T, Jansen JH, Martens JHA, van der Reijden BA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39633068"},{"title01":"Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Na\u00efve Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA","title02":"Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Na\u00efve Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA","journal":"J Clin Oncol","issue":"2024 Dec 8:JCO2402265. doi: 10.1200\/JCO-24-02265. Online ahead of print.","author":"Shadman M, Munir T, Robak T, Brown JR, Kahl BS, Ghia P, Giannopoulos K, \u0160imkovi\u010d M, \u00d6sterborg A, Laurenti L, Walker PA, Opat SS, Ciepluch H, Greil R, Hanna M, Tani M, Trn\u011bn\u00fd M, Brander D, Flinn IW, Grosicki S, Verner E, Tedeschi A, de Guibert S, Tumyan G, Laribi K, Garc\u00eda-Marco JA, Li JY, Tian T, Liu Y, Korolkiewicz R, Szeto A, Tam CS, Jurczak W.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39647999"},{"title01":"hu128.1, a humanized antibody targeting transferrin receptor 1, blocks erythroleukemia growth in xenograft mouse models","title02":"hu128.1, a humanized antibody targeting transferrin receptor 1, blocks erythroleukemia growth in xenograft mouse models","journal":"Haematologica","issue":"2024 Dec 12. doi: 10.3324\/haematol.2024.286518. Online ahead of print.","author":"Daniels-Wells TR, Candelaria PV, Rodriguez AM, Poul MA, Penichet ML.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39665200"},{"title01":"Fatal thrombotic microangiopathy during induction for acute myeloid leukemia: A case report and review of vascular complications in germline GATA2 haploinsufficiency","title02":"Fatal thrombotic microangiopathy during induction for acute myeloid leukemia: A case report and review of vascular complications in germline GATA2 haploinsufficiency","journal":"Br J Haematol","issue":"2024 Dec 8. doi: 10.1111\/bjh.19935. Online ahead of print.","author":"Frost EL, Chonat S, Williams KM, Aumann W, Stevenson J, Yin J, Schniederjan M, Arnold S, Schoettler ML.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39648368"},{"title01":"Clinical perspectives on post-induction maintenance therapy in patients with acute myeloid leukaemia in remission who are ineligible for allogeneic haematopoietic stem cell transplantation","title02":"Clinical perspectives on post-induction maintenance therapy in patients with acute myeloid leukaemia in remission who are ineligible for allogeneic haematopoietic stem cell transplantation","journal":"Br J Haematol","issue":"2024 Dec 2. doi: 10.1111\/bjh.19924. Online ahead of print.","author":"Sweet K, Cluzeau T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39622271"},{"title01":"Single-cell epigenetic and clonal analysis decodes disease progression in pediatric acute myeloid leukemia","title02":"Single-cell epigenetic and clonal analysis decodes disease progression in pediatric acute myeloid leukemia","journal":"Blood","issue":"2024 Dec 11:blood.2024025618. doi: 10.1182\/blood.2024025618. Online ahead of print.","author":"Cui B, Ai L, Lei M, Duan Y, Tang C, Zhang J, Gao Y, Li X, Zhu C, Zhang Y, Zhu X, Isobe T, Yang W, Gottgens B, Zhu P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39661948"},{"title01":"Honing CAR T cells to tackle acute myeloid leukemia","title02":"Honing CAR T cells to tackle acute myeloid leukemia","journal":"Blood","issue":"2024 Dec 4:blood.2024024063. doi: 10.1182\/blood.2024024063. Online ahead of print.","author":"Haubner S, Subklewe M, Sadelain M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39630061"},{"title01":"Incidence of Richter transformation of chronic lymphocytic leukemia\/small lymphocytic lymphoma in the targeted therapy era","title02":"Incidence of Richter transformation of chronic lymphocytic leukemia\/small lymphocytic lymphoma in the targeted therapy era","journal":"Leukemia","issue":"2024 Dec 10. doi: 10.1038\/s41375-024-02492-4. Online ahead of print.","author":"Hampel PJ, Rabe KG, Wang Y, Hwang SR, Kenderian SS, Muchtar E, Leis JF, Koehler AB, Tsang M, Hilal T, Parrondo R, Bailen RJ, Schwager SM, Hanson CA, Braggio E, Slager SL, Shi M, Zepeda-Mendoza CJ, Van Dyke DL, Shanafelt TD, King RL, Call TG, Kay NE, Ding W, Parikh SA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39658628"},{"title01":"Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: a single-centre, single-arm, phase 2 trial","title02":"Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: a single-centre, single-arm, phase 2 trial","journal":"Lancet Haematol","issue":"2024 Dec 6:S2352-3026(24)00345-4. doi: 10.1016\/S2352-3026(24)00345-4. Online ahead of print.","author":"Alderuccio JP, Alencar AJ, Schatz JH, Kuker RA, Pongas G, Reis IM, Lekakis LJ, Spiegel JY, Sandoval-Sus J, Beitinjaneh A, Stanchina MD, Trabolsi A, Lossos IS, Rosenblatt JD, Lessen DS, Moskowitz CH.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39662486"},{"title01":"Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Na\u00efve Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA","title02":"Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Na\u00efve Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA","journal":"J Clin Oncol","issue":"2024 Dec 8:JCO2402265. doi: 10.1200\/JCO-24-02265. Online ahead of print.","author":"Shadman M, Munir T, Robak T, Brown JR, Kahl BS, Ghia P, Giannopoulos K, \u0160imkovi\u010d M, \u00d6sterborg A, Laurenti L, Walker PA, Opat SS, Ciepluch H, Greil R, Hanna M, Tani M, Trn\u011bn\u00fd M, Brander D, Flinn IW, Grosicki S, Verner E, Tedeschi A, de Guibert S, Tumyan G, Laribi K, Garc\u00eda-Marco JA, Li JY, Tian T, Liu Y, Korolkiewicz R, Szeto A, Tam CS, Jurczak W.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39647999"},{"title01":"Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma","title02":"Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma","journal":"J Clin Oncol","issue":"2024 Dec 11:JCO2401278. doi: 10.1200\/JCO-24-01278. Online ahead of print.","author":"Torka P, Feldman T, Savage KJ, Ganesan N, Drill E, Hancock H, Davey T, Perez L, Capadona C, Subzwari S, Galasso N, Yang J, Post M, Boardman A, Caron P, David K, Epstein-Peterson Z, Falchi L, Ghione P, Hamlin P, Horwitz SM, Intlekofer AM, Johnson W, Kumar A, Lue J, Noy A, Owens C, Palomba ML, Salles GA, Steiner R, Stuver R, Vardhana S, Yahalom J, Dogan A, Zelenetz AD, Sch\u00f6der H, Moskowitz AJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39661923"},{"title01":"Characterization of tumor microenvironment and cell interaction patterns in testicular and diffuse large B-cell lymphomas","title02":"Characterization of tumor microenvironment and cell interaction patterns in testicular and diffuse large B-cell lymphomas","journal":"Haematologica","issue":"2024 Dec 12. doi: 10.3324\/haematol.2024.286267. Online ahead of print.","author":"Autio M, Br\u00fcck O, Pollari M, Karjalainen-Lindsberg ML, Beiske K, J\u00f8rgensen JM, Holte H, Pellinen T, Leivonen SK, Lepp\u00e4 S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39665214"},{"title01":"Dexamethasone is associated with reduced frequency and intensity of cytokine release syndrome compared with alternative corticosteroid regimens as premedication for glofitamab in patients with relapsed \/ refractory large B-cell lymphoma","title02":"Dexamethasone is associated with reduced frequency and intensity of cytokine release syndrome compared with alternative corticosteroid regimens as premedication for glofitamab in patients with relapsed \/ refractory large B-cell lymphoma","journal":"Haematologica","issue":"2024 Nov 28. doi: 10.3324\/haematol.2024.286257. Online ahead of print.","author":"Falchi L, Hutchings M, Carlo-Stella C, Morschhauser F, Dickinson M, Cartron G, Khan C, Tani M, Martinez-Lopez J, Bartlett NL, Salar A, Brody JD, Lepp\u00e4 S, Berthier A, Kallemeijn M, Relf J, Tchaleu FB, Lundberg L, Bachy E.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39605203"},{"title01":"Identification of a clinicopathologic prognostic index for newly diagnosed large B cell lymphoma patients treated with R-CHOP","title02":"Identification of a clinicopathologic prognostic index for newly diagnosed large B cell lymphoma patients treated with R-CHOP","journal":"Haematologica","issue":"2024 Nov 28. doi: 10.3324\/haematol.2024.286560. Online ahead of print.","author":"Ni V, Nasta SD, Barta SK, Schuster SJ, Chong EA, Svoboda J, Morrissette JJD, Barlev A, Bagg A, Priore SF, Landsburg DJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39605216"},{"title01":"Quality of life in advanced-stage, asymptomatic, non-bulky follicular lymphoma treated with rituximab shows significant improvement compared with watchful-waiting","title02":"Quality of life in advanced-stage, asymptomatic, non-bulky follicular lymphoma treated with rituximab shows significant improvement compared with watchful-waiting","journal":"Br J Haematol","issue":"2024 Nov 27. doi: 10.1111\/bjh.19918. Online ahead of print.","author":"Marzolini MAV, Qian W, Clifton-Hadley L, Patrick P, Warden J, Stevens L, Pocock CFE, Miall F, Cunningham D, Stephens R, Walewski J, Johnston A, Seymour JF, Linch DC, Ardeshna KM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39604791"},{"title01":"The GATA-3-dependent transcriptome and tumor microenvironment are regulated by eIF4E and XPO1 in T-cell lymphomas","title02":"The GATA-3-dependent transcriptome and tumor microenvironment are regulated by eIF4E and XPO1 in T-cell lymphomas","journal":"Blood","issue":"2024 Dec 9:blood.2024025484. doi: 10.1182\/blood.2024025484. Online ahead of print.","author":"Kady N, Abdelrahman S, Rauf A, Burgess A, Weiss J, Gunasekara H, Ramseier NT, Maine IP, Zevallos-Morales A, Perez-Silos V, Wolfe A, Hristov A, Brown NA, Inamdar KV, Sverdlov M, Hu YS, Murga-Zamalloa C, Wang C, Wilcox RA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39652777"},{"title01":"Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Advanced-Stage Classical Hodgkin Lymphoma","title02":"Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Advanced-Stage Classical Hodgkin Lymphoma","journal":"Blood","issue":"2024 Dec 2:blood.2024024681. doi: 10.1182\/blood.2024024681. Online ahead of print.","author":"Lee HJ, Ramchandren R, Friedman J, Melear JM, Flinn IW, Burke JM, Linhares Y, Gonzales PA, Peterson M, Raval M, Chintapatla R, Feldman TA, Yimer HA, Islas-Ohlmayer M, Patel A, Metheny L, Dean A, Rana V, Gandhi MD, Renshaw JS, Ho L, Fanale MA, Guo W, Yasenchak CA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39622165"},{"title01":"Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma","title02":"Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma","journal":"N Engl J Med","issue":"2024 Dec 9. doi: 10.1056\/NEJMoa2409029. Online ahead of print.","author":"Dimopoulos MA, Voorhees PM, Schjesvold F, Cohen YC, Hungria V, Sandhu I, Lindsay J, Baker RI, Suzuki K, Kosugi H, Levin MD, Beksac M, Stockerl-Goldstein K, Oriol A, Mikala G, Garate G, Theunissen K, Spicka I, Mylin AK, Bringhen S, Uttervall K, Pula B, Medvedova E, Cowan AJ, Moreau P, Mateos MV, Goldschmidt H, Ahmadi T, Sha L, Cortoos A, Katz EG, Rousseau E, Li L, Dennis RM, Carson R, Rajkumar SV; AQUILA Investigators.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39652675"},{"title01":"Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial","title02":"Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial","journal":"J Clin Oncol","issue":"2024 Dec 9:JCO2402266. doi: 10.1200\/JCO-24-02266. Online ahead of print.","author":"Mai EK, Bertsch U, Pozek E, Fenk R, Besemer B, Hanoun C, Schroers R, von Metzler I, H\u00e4nel M, Mann C, Leypoldt LB, Heilmeier B, Huhn S, Vogel SK, Hundemer M, Scheid C, Blau IW, Luntz S, Weinhold N, Tichy D, Holderried TAW, Trautmann-Grill K, Gezer D, Klaiber-Hakimi M, M\u00fcller M, Shumilov E, Knauf W, Michel CS, Geer T, Riesenberg H, Lutz C, Raab MS, Benner A, Hoffmann M, Weisel KC, Salwender HJ, Goldschmidt H; German-Speaking Myeloma Multicenter Group (GMMG) HD7 Investigators; German-speaking Myeloma Multicenter Group (GMMG) HD7.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39652594"},{"title01":"Phase I Trial of MCARH109, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Updated Analysis","title02":"Phase I Trial of MCARH109, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Updated Analysis","journal":"J Clin Oncol","issue":"2024 Dec 4:JCO2401785. doi: 10.1200\/JCO-24-01785. Online ahead of print.","author":"Jurgens EM, Firestone RS, Chaudhari J, Hosszu K, Devlin SM, Shah UA, Landa J, McAvoy DP, Lesokhin AM, Korde N, Hassoun H, Tan CR, Hultcrantz M, Shah GL, Landau HJ, Chung DJ, Scordo M, Eren OC, Dogan A, Giralt SA, Park JH, Rivi\u00e8re I, Brentjens RJ, Smith EL, Wang X, Usmani SZ, Mailankody S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39631041"},{"title01":"Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials","title02":"Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials","journal":"Haematologica","issue":"2024 Nov 28. doi: 10.3324\/haematol.2024.286658. Online ahead of print.","author":"Martino EA, Derudas D, Rossi E, Terlizzi S, Reddiconto G, Stefanoni P, Micozzi J, Mangiacavalli S, Zamagni E, Offidani M, Furlan A, Buda G, Lotti F, Liberatore C, Lazzaro A, Pepa RD, Bertuglia G, Barbieri E, Conticello C, De Magistris C, De Paoli L, Bongarzoni V, Cafro AM, Mele A, Benvenuti P, Cerchione C, Botta C, Antonioli E, Sgherza N, Aquino S, Mele G, Baril\u00e0 G, Palmieri S, Annibali O, Bianco R, Febbo MA, Casaluci GM, Rago A, Fontana R, Farina F, Vigna E, Bruzzese A, Mancuso K, Nappi D, Mor\u00e8 S, Rivolti E, Califano C, Amendola A, Roccotelli D, Lombardo A, Citro A, Uccello G, Zambello R, Maggi A, Neri S, Monachesi M, Gozzetti A, Montefusco V, Brunori M, Cotzia E, Pietrantuono G, Quinto AM, Amico V, Di Renzo N, Coscia M, Galli M, De Stefano V, Petrucci MT, Neri A, Di Raimondo F, Morabito F, Musto P, Gentile M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39605207"},{"title01":"Novel CCL3-HMGB1 signaling axis regulating osteocyte RANKL expression in multiple myeloma","title02":"Novel CCL3-HMGB1 signaling axis regulating osteocyte RANKL expression in multiple myeloma","journal":"Haematologica","issue":"2024 Nov 28. doi: 10.3324\/haematol.2024.286484. Online ahead of print.","author":"Anloague A, Sabol HM, Kaur J, Khan S, Ashby C, Schinke C, Barnes CL, Alturkmani F, Ambrogini E, Gundesen MT, Lund T, Amstrup AK, Andersen TL, Diaz-delCastillo M, Roodman GD, Bellido T, Delgado-Calle J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39605211"},{"title01":"Acid ceramidase controls proteasome inhibitor resistance and is a novel therapeutic target for the treatment of relapsed \/ refractory multiple myeloma","title02":"Acid ceramidase controls proteasome inhibitor resistance and is a novel therapeutic target for the treatment of relapsed \/ refractory multiple myeloma","journal":"Haematologica","issue":"2024 Dec 5. doi: 10.3324\/haematol.2024.285587. Online ahead of print.","author":"Bishop RT, Li T, Sudalagunta P, Nasr M, Nyman KJ, Alugubelli RR, Meads M, Frieling J, Nerlakanti N, Tauro M, Fang B, Grant S, Koomen J, Silva AS, Shain KH, Lynch CC.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39633543"},{"title01":"Bone-independent extramedullary disease is associated with inferior overall survival in multiple myeloma patients: a single center, real-world experience","title02":"Bone-independent extramedullary disease is associated with inferior overall survival in multiple myeloma patients: a single center, real-world experience","journal":"Haematologica","issue":"2024 Dec 5. doi: 10.3324\/haematol.2024.286409. Online ahead of print.","author":"Xu K, Agbuduwe C, Kanellias N, Wilson W, McMillan A, Papanikolaou X, Lee L, Popat R, Sive J, Rabin N, Yong K, Parcharidou A, Kyriakou C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39633554"},{"title01":"Impact of body mass index on outcomes of multiple myeloma patients undergoing upfront autologous stem cell transplant","title02":"Impact of body mass index on outcomes of multiple myeloma patients undergoing upfront autologous stem cell transplant","journal":"Br J Haematol","issue":"2024 Nov 28. doi: 10.1111\/bjh.19937. Online ahead of print.","author":"Marcoux C, Pasyar S, Milton DR, Khan HN, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Neupane N, Lee HC, Patel KK, Tang G, Aljawai Y, Kebriaei P, Thomas SK, Orlowski RZ, Shpall EJ, Champlin R, Qazilbash MH, Pasvolsky O.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39610225"},{"title01":"Autologous stem cell transplantation for multiple myeloma patients whose myeloma-defining event was SLiM","title02":"Autologous stem cell transplantation for multiple myeloma patients whose myeloma-defining event was SLiM","journal":"Br J Haematol","issue":"2024 Nov 29. doi: 10.1111\/bjh.19936. Online ahead of print.","author":"Vaxman I, Kumar S, Cohen I, Simony S, Dispenzieri A, Buadi F, Dingli D, Muchtar E, Kapoor P, Hogan W, Hayman S, Leung N, Gonsalves W, Kourelis T, Warsame R, Gertz M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39613336"},{"title01":"Reengaging life post-BCMA for myeloma","title02":"Reengaging life post-BCMA for myeloma","journal":"Blood","issue":"2024 Dec 5;144(23):2365-2367.","author":"Quach H.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39636649"},{"title01":"Moving forward in good KarMMa in myeloma","title02":"Moving forward in good KarMMa in myeloma","journal":"Blood","issue":"2024 Dec 5;144(23):2367-2369.","author":"Bianchi G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39636652"},{"title01":"ADAR1-regulated cytoplasmic dsRNA-sensing pathway is a novel mechanism of lenalidomide resistance in multiple myeloma","title02":"ADAR1-regulated cytoplasmic dsRNA-sensing pathway is a novel mechanism of lenalidomide resistance in multiple myeloma","journal":"Blood","issue":"2024 Dec 9:blood.2024024429. doi: 10.1182\/blood.2024024429. Online ahead of print.","author":"Koh MY, Chung TH, Tang NXN, Toh SHM, Zhou J, Tan TK, Chen L, Chng WJ, Teoh PJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39652772"},{"title01":"Tumor burden quantified by Soluble B-Cell Maturation Antigen and Metabolic Tumor Volume determine myeloma CAR-T outcomes","title02":"Tumor burden quantified by Soluble B-Cell Maturation Antigen and Metabolic Tumor Volume determine myeloma CAR-T outcomes","journal":"Blood","issue":"2024 Dec 9:blood.2024024965. doi: 10.1182\/blood.2024024965. Online ahead of print.","author":"Freeman CL, Noble J, Menges M, Villanueva R, Nakashima JY, Figura NB, Tonseth RP, Idiaquez DW, Skelson L, Smith EC, Abraham-Miranda J, Corallo S, De Avila G, Castaneda Puglianini O, Liu HD, Alsina M, Nishihori T, Shain KH, Baz RC, Blue BJ, Grajales-Cruz A, Koomen JM, Atkins RM, Hansen DK, Siqueira Silva A, Kim J, Balagurunathan Y, Locke FL.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39652773"},{"title01":"Efficacy and Safety of Daratumumab in Intermediate\/High-risk Smoldering Multiple Myeloma: Final Analysis of CENTAURUS","title02":"Efficacy and Safety of Daratumumab in Intermediate\/High-risk Smoldering Multiple Myeloma: Final Analysis of CENTAURUS","journal":"Blood","issue":"2024 Dec 9:blood.2024025897. doi: 10.1182\/blood.2024025897. Online ahead of print.","author":"Landgren CO, Chari A, Cohen YC, Spencer A, Voorhees PM, Sandhu I, Jenner MW, Smith D, Cavo M, van de Donk NWCJ, Beksac M, Moreau P, Goldschmidt H, Vieyra D, Sha L, Li L, Rousseau E, Dennis RM, Carson R, Hofmeister CC.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39652826"},{"title01":"Targeted interferon therapy with modakafusp alfa for relapsed or refractory multiple myeloma","title02":"Targeted interferon therapy with modakafusp alfa for relapsed or refractory multiple myeloma","journal":"Blood","issue":"2024 Dec 4:blood.2024026124. doi: 10.1182\/blood.2024026124. Online ahead of print.","author":"Vogl DT, Atrash S, Holstein SA, Nadeem O, Benson DM Jr, Chaudhry M, Biran N, Suryanarayan K, Li C, Liu Y, Collins SC, Parot X, Kaufman JL.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39630057"},{"title01":"The impact of patient ethnicity on haematopoietic cell transplantation outcome: a retrospective cohort study on the UK experience","title02":"The impact of patient ethnicity on haematopoietic cell transplantation outcome: a retrospective cohort study on the UK experience","journal":"Lancet Haematol","issue":"2024 Dec;11(12):e916-e926.","author":"Mayor NP, Szydlo RM, Sheikh Y, Lee J, Pearce RM, Farrow C, Agapiou M, Rao K, Orchard K, Olavarria E, Marsh SGE, Snowden JA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39638542"},{"title01":"Post-transplant erythrocytosis after kidney transplant and acute renal infarct","title02":"Post-transplant erythrocytosis after kidney transplant and acute renal infarct","journal":"Lancet","issue":"2024 Nov 30;404(10468):2197.","author":"\u00d6zpolat HT, Ariyamuthu VK.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39615999"},{"title01":"Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial","title02":"Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial","journal":"J Clin Oncol","issue":"2024 Dec 9:JCO2402266. doi: 10.1200\/JCO-24-02266. Online ahead of print.","author":"Mai EK, Bertsch U, Pozek E, Fenk R, Besemer B, Hanoun C, Schroers R, von Metzler I, H\u00e4nel M, Mann C, Leypoldt LB, Heilmeier B, Huhn S, Vogel SK, Hundemer M, Scheid C, Blau IW, Luntz S, Weinhold N, Tichy D, Holderried TAW, Trautmann-Grill K, Gezer D, Klaiber-Hakimi M, M\u00fcller M, Shumilov E, Knauf W, Michel CS, Geer T, Riesenberg H, Lutz C, Raab MS, Benner A, Hoffmann M, Weisel KC, Salwender HJ, Goldschmidt H; German-Speaking Myeloma Multicenter Group (GMMG) HD7 Investigators; German-speaking Myeloma Multicenter Group (GMMG) HD7.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39652594"},{"title01":"Five-year outcomes of CD19 followed by CD22 chimeric antigen receptor T-cell therapy in B-cell acute lymphoblastic leukemia patients who relapsed after allo-transplantation","title02":"Five-year outcomes of CD19 followed by CD22 chimeric antigen receptor T-cell therapy in B-cell acute lymphoblastic leukemia patients who relapsed after allo-transplantation","journal":"Haematologica","issue":"2024 Dec 12. doi: 10.3324\/haematol.2024.286534. Online ahead of print.","author":"Liu S, An L, Yin Z, Lin Y, Ling Z, Deng B, Yu X, Zheng Q, Zhao D, Wu T, Chang AH, Tong C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39665213"},{"title01":"Donor cytomegalovirus serology impacts overall survival in children receiving first unrelated hematopoietic stem cell transplant for acute leukemia: European Society of Bone Marrow Transplantation Pediatric Diseases Working Party Study","title02":"Donor cytomegalovirus serology impacts overall survival in children receiving first unrelated hematopoietic stem cell transplant for acute leukemia: European Society of Bone Marrow Transplantation Pediatric Diseases Working Party Study","journal":"Haematologica","issue":"2024 Nov 28. doi: 10.3324\/haematol.2024.286082. Online ahead of print.","author":"Ince E, Galimard JE, Ifversen M, Dalissier A, Szmit Z, Mirci-Danicar O, Locatelli F, Sedlacek P, Styczynski J, Dalle JH, Renard C, Balduzzi A, Lankester A, Bierings M, Fagioli F, Kielsen K, Rialland F, B\u00fcchner J, Taskinen M, Wynn R, Jubert C, Michel G, Pichler H, Krivan G, Cesaro S, Corbacioglu S, Meisel R, Kalwak K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39605204"},{"title01":"Letermovir prophylaxis for cytomegalovirus is associated with risk of post-transplant lymphoproliferative disorders after haploidentical stem cell transplantation","title02":"Letermovir prophylaxis for cytomegalovirus is associated with risk of post-transplant lymphoproliferative disorders after haploidentical stem cell transplantation","journal":"Haematologica","issue":"2024 Nov 28. doi: 10.3324\/haematol.2024.286265. Online ahead of print.","author":"Pei XY, Huang Q, Luo LJ, Sun HL, Liu J, Sun YQ, Mo XD, Lv M, Liu DH, Ma HY, Wu YW, Xu LP, Wang Y, Zhang XH, Chen L, Huang XJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39605206"},{"title01":"Intestinal perforation following allogeneic stem cell transplantation caused by Epstein-Barr virus-positive mucocutaneous ulcer","title02":"Intestinal perforation following allogeneic stem cell transplantation caused by Epstein-Barr virus-positive mucocutaneous ulcer","journal":"Haematologica","issue":"2024 Dec 5. doi: 10.3324\/haematol.2024.286488. Online ahead of print.","author":"Hirschb\u00fchl K, Schaller T, M\u00e4rkl B, Amerein A, Gebhard M, Braun G, Wasserberg S, Sala E, Trepel M, Schmid C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39633546"},{"title01":"Does size matter? Center-specific characteristics and survival after allogeneic hematopoietic cell transplantation for acute myeloid leukemia: an analysis of the German Registry for Stem Cell Transplantation and Cell Therapy","title02":"Does size matter? Center-specific characteristics and survival after allogeneic hematopoietic cell transplantation for acute myeloid leukemia: an analysis of the German Registry for Stem Cell Transplantation and Cell Therapy","journal":"Haematologica","issue":"2024 Dec 5. doi: 10.3324\/haematol.2024.286385. Online ahead of print.","author":"Bethge W, Flossdorf S, Hanke F, Schmid C, Ringhoffer M, Klein S, Hertenstein B, Schetelig J, Stelljes M, Schroeder T, Blau IW, Ayuk F, Eder M, Zeiser R, Fleischhauer K, Kr\u00f6ger N, Dreger P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39633549"},{"title01":"Impact of body mass index on outcomes of multiple myeloma patients undergoing upfront autologous stem cell transplant","title02":"Impact of body mass index on outcomes of multiple myeloma patients undergoing upfront autologous stem cell transplant","journal":"Br J Haematol","issue":"2024 Nov 28. doi: 10.1111\/bjh.19937. Online ahead of print.","author":"Marcoux C, Pasyar S, Milton DR, Khan HN, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Neupane N, Lee HC, Patel KK, Tang G, Aljawai Y, Kebriaei P, Thomas SK, Orlowski RZ, Shpall EJ, Champlin R, Qazilbash MH, Pasvolsky O.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39610225"},{"title01":"Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children","title02":"Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children","journal":"N Engl J Med","issue":"2024 Dec 7. doi: 10.1056\/NEJMoa2411680. Online ahead of print.","author":"Gupta S, Rau RE, Kairalla JA, Rabin KR, Wang C, Angiolillo AL, Alexander S, Carroll AJ, Conway S, Gore L, Kirsch I, Kubaney HR, Li AM, McNeer JL, Militano O, Miller TP, Moyer Y, O'Brien MM, Okada M, Reshmi SC, Shago M, Wagner E, Winick N, Wood BL, Haworth-Wright T, Zaman F, Zugmaier G, Zupanec S, Devidas M, Hunger SP, Teachey DT, Raetz EA, Loh ML.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39651791"},{"title01":"Five-year outcomes of CD19 followed by CD22 chimeric antigen receptor T-cell therapy in B-cell acute lymphoblastic leukemia patients who relapsed after allo-transplantation","title02":"Five-year outcomes of CD19 followed by CD22 chimeric antigen receptor T-cell therapy in B-cell acute lymphoblastic leukemia patients who relapsed after allo-transplantation","journal":"Haematologica","issue":"2024 Dec 12. doi: 10.3324\/haematol.2024.286534. Online ahead of print.","author":"Liu S, An L, Yin Z, Lin Y, Ling Z, Deng B, Yu X, Zheng Q, Zhao D, Wu T, Chang AH, Tong C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39665213"},{"title01":"Donor cytomegalovirus serology impacts overall survival in children receiving first unrelated hematopoietic stem cell transplant for acute leukemia: European Society of Bone Marrow Transplantation Pediatric Diseases Working Party Study","title02":"Donor cytomegalovirus serology impacts overall survival in children receiving first unrelated hematopoietic stem cell transplant for acute leukemia: European Society of Bone Marrow Transplantation Pediatric Diseases Working Party Study","journal":"Haematologica","issue":"2024 Nov 28. doi: 10.3324\/haematol.2024.286082. Online ahead of print.","author":"Ince E, Galimard JE, Ifversen M, Dalissier A, Szmit Z, Mirci-Danicar O, Locatelli F, Sedlacek P, Styczynski J, Dalle JH, Renard C, Balduzzi A, Lankester A, Bierings M, Fagioli F, Kielsen K, Rialland F, B\u00fcchner J, Taskinen M, Wynn R, Jubert C, Michel G, Pichler H, Krivan G, Cesaro S, Corbacioglu S, Meisel R, Kalwak K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39605204"},{"title01":"Therapy for acute myeloid leukemia in older and unfit adults","title02":"Therapy for acute myeloid leukemia in older and unfit adults","journal":"Haematologica","issue":"2024 Dec 1;109(12):3832-3834. doi: 10.3324\/haematol.2024.286233.","author":"Forsberg M, Konopleva M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39618293"},{"title01":"Complete remission of NUP98 fusion-positive acute myeloid leukemia with the covalent menin inhibitor BMF-219, icovamenib","title02":"Complete remission of NUP98 fusion-positive acute myeloid leukemia with the covalent menin inhibitor BMF-219, icovamenib","journal":"Haematologica","issue":"2024 Dec 5. doi: 10.3324\/haematol.2024.286537. Online ahead of print.","author":"Carraway HE, Nakitandwe J, Cacovean A, Ma Y, Munneke B, Waghmare G, Mandap C, Ahmed U, Kowalczyk N, Butler T, Morris SW.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39633542"},{"title01":"Does size matter? Center-specific characteristics and survival after allogeneic hematopoietic cell transplantation for acute myeloid leukemia: an analysis of the German Registry for Stem Cell Transplantation and Cell Therapy","title02":"Does size matter? Center-specific characteristics and survival after allogeneic hematopoietic cell transplantation for acute myeloid leukemia: an analysis of the German Registry for Stem Cell Transplantation and Cell Therapy","journal":"Haematologica","issue":"2024 Dec 5. doi: 10.3324\/haematol.2024.286385. Online ahead of print.","author":"Bethge W, Flossdorf S, Hanke F, Schmid C, Ringhoffer M, Klein S, Hertenstein B, Schetelig J, Stelljes M, Schroeder T, Blau IW, Ayuk F, Eder M, Zeiser R, Fleischhauer K, Kr\u00f6ger N, Dreger P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39633549"},{"title01":"Depletion of the RNA binding protein QKI and circular RNA dysregulation in T-cell acute lymphoblastic leukemia","title02":"Depletion of the RNA binding protein QKI and circular RNA dysregulation in T-cell acute lymphoblastic leukemia","journal":"Haematologica","issue":"2024 Dec 5. doi: 10.3324\/haematol.2024.285971. Online ahead of print.","author":"Buratin A, Palhais B, Gaffo E, Roels J, Morscio J, Van Laere J, Orsi S, Te Kronnie G, Van Vlierberghe P, Ntziachristos P, Bortoluzzi S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39633556"},{"title01":"miR-196b-Oct1\/2 axis regulates DNMT3A-mutant AML pathogenesis","title02":"miR-196b-Oct1\/2 axis regulates DNMT3A<\/i>-mutant AML pathogenesis","journal":"Leukemia","issue":"2024 Nov 23. doi: 10.1038\/s41375-024-02456-8. Online ahead of print.","author":"Lawler ME, Goetz ML, Romer-Seibert JS, Gamlen HA, McGlinn E, Meyer SE.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39580581"},{"title01":"Investigating the influence of germline ATM variants in chronic lymphocytic leukemia on cancer vulnerability","title02":"Investigating the influence of germline ATM<\/i> variants in chronic lymphocytic leukemia on cancer vulnerability","journal":"Haematologica","issue":"2024 Nov 21. doi: 10.3324\/haematol.2024.286031. Online ahead of print.","author":"Azevedo RS, Morelli F, Mashima K, Fardoun R, Tyekucheva S, Fernandes S, Shupe S, Terra M, Patel A, Davids MS, Yu J, Brown JR.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39568439"},{"title01":"Genocopy of EVI1-AML with paraneoplastic diabetes insipidus: PRDM16 overexpression by t(1;2)(p36;p21) and enhancer hijacking","title02":"Genocopy of EVI1<\/i>-AML with paraneoplastic diabetes insipidus: PRDM16<\/i> overexpression by t(1;2)(p36;p21) and enhancer hijacking","journal":"Br J Haematol","issue":"2024 Nov 26. doi: 10.1111\/bjh.19922. Online ahead of print.","author":"List J, Sollier E, Brown-Burke F, Kelly K, Pfeifer D, Shlyakhto V, Maas-Bauer K, Pantic M, Plass C, L\u00fcbbert M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39587921"},{"title01":"Dar-ting at CD38 in T-cell leukemias","title02":"Dar<\/i>-ting at CD38 in T-cell leukemias","journal":"Blood","issue":"2024 Nov 21;144(21):2162-2164.","author":"Senapati J, Jabbour E.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39570597"},{"title01":"Nanobody-based Naturally Selected CD7-Targeted CAR-T Therapy for Acute Myeloid Leukemia","title02":"Nanobody-based Naturally Selected CD7-Targeted CAR-T Therapy for Acute Myeloid Leukemia","journal":"Blood","issue":"2024 Nov 19:blood.2024024861. doi: 10.1182\/blood.2024024861. Online ahead of print.","author":"Lu P, Zhang X, Yang J, Li J, Qiu L, Gong M, Wang H, Chen J, Liu H, Xiong M, Liu Y, Wang L.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39561281"},{"title01":"Development of ALL-Hematotox (ALL-HT): Predicting post CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia","title02":"Development of ALL-Hematotox (ALL-HT): Predicting post CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia","journal":"Blood","issue":"2024 Nov 19:blood.2024025910. doi: 10.1182\/blood.2024025910. Online ahead of print.","author":"Nair MS, Silbert SK, Rejeski K, Wilson KA, Lamble AJ, Valtis YK, Yates B, Morales Arana A, Shouval R, Curran KJ, Gardner RA, Shalabi H, Annesley C, Park JH, Subklewe M, Shah NN.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39561284"},{"title01":"Bivalent CD47 Immunotoxin for Targeted Therapy of T-Cell Acute Lymphoblastic Leukemia","title02":"Bivalent CD47 Immunotoxin for Targeted Therapy of T-Cell Acute Lymphoblastic Leukemia","journal":"Blood","issue":"2024 Nov 19:blood.2024025277. doi: 10.1182\/blood.2024025277. Online ahead of print.","author":"Ma J, Wang Z, Mintzlaff D, Zhang H, Ramakrishna R, Davila E, Witkowski MT, Lucia MS, Schwartz MS, Pomfret EA, Mathes DW, Wang Z.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39561285"},{"title01":"Aggressive Lymphoma after CD19 CAR T-Cell Therapy","title02":"Aggressive Lymphoma after CD19 CAR T-Cell Therapy","journal":"N Engl J Med","issue":"2024 Oct 3;391(13):1217-1226.","author":"Kobbe G, Br\u00fcggemann M, Baermann BN, Wiegand L, Trautmann H, Yousefian S, Libertini S, Menssen HD, Maier HJ, Ulrich P, Gao J, Bruch PM, Liebers N, Radujkovic A, Seifert M, Schniederjohann C, Paramasivam N, Fitzgerald D, Seidel M, Esposito I, Germing U, Cadeddu RP, Nachtkamp K, J\u00e4ger P, Ulrych T, Fischer JC, Rox JM, Giesel F, Koch R, Antoch G, Distler JHW, Meuth SG, Jacobsen M, H\u00fcbschmann D, Lu J, Iaccarino I, Haas S, Damm F, Dietrich S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39589371"},{"title01":"Dimethyl fumarate and extracorporeal photopheresis combination-therapy synergize in inducing specific cell death and long-term remission in cutaneous T cell lymphoma","title02":"Dimethyl fumarate and extracorporeal photopheresis combination-therapy synergize in inducing specific cell death and long-term remission in cutaneous T cell lymphoma","journal":"Leukemia","issue":"2024 Nov 23. doi: 10.1038\/s41375-024-02479-1. Online ahead of print.","author":"\u015eener \u00d6\u00c7, Melchers S, Tengler L, Beltzig PL, Albrecht JD, T\u00fcmen D, G\u00fclow K, Utikal JS, Goerdt S, Hein T, Nicolay JP.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39580583"},{"title01":"Comprehensive genomic analysis reveals molecular heterogeneity in pediatric ALK-positive anaplastic large cell lymphoma","title02":"Comprehensive genomic analysis reveals molecular heterogeneity in pediatric ALK-positive anaplastic large cell lymphoma","journal":"Leukemia","issue":"2024 Nov 26. doi: 10.1038\/s41375-024-02468-4. Online ahead of print.","author":"Shaw TI, Pounds S, Cao X, Ma J, Palacios G, Mason J, Perkins S, Wu G, Fan Y, Wang J, Zhou X, Obermayer A, Kinney MC, Kraveka J, Gross T, Sandlund J, Zhang J, Mullighan C, Lim MS, Leventaki V.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39592809"},{"title01":"Glofit-GemOx: a new treatment paradigm in relapsed or refractory diffuse large B-cell lymphoma?","title02":"Glofit-GemOx: a new treatment paradigm in relapsed or refractory diffuse large B-cell lymphoma?","journal":"Lancet","issue":"2024 Nov 16;404(10466):1899-1901.","author":"Sureda A, Pavlosky A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39550162"},{"title01":"Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial","title02":"Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial","journal":"Lancet","issue":"2024 Nov 16;404(10466):1940-1954.","author":"Abramson JS, Ku M, Hertzberg M, Huang HQ, Fox CP, Zhang H, Yoon DH, Kim WS, Abdulhaq H, Townsend W, Herbaux C, Zaucha JM, Zhang QY, Chang H, Liu Y, Cheah CY, Ghesquieres H, Simko S, Orellana-Noia V, Ta R, Relf J, Dixon M, Kallemeijn M, Mulvihill E, Huang H, Lundberg L, Gregory GP.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39550172"},{"title01":"The End of the Golden Weather: therapeutic strategies for mantle cell lymphoma relapsed or refractory to covalent BTK inhibitors","title02":"The End of the Golden Weather: therapeutic strategies for mantle cell lymphoma relapsed or refractory to covalent BTK inhibitors","journal":"Haematologica","issue":"2024 Nov 14. doi: 10.3324\/haematol.2024.286205. Online ahead of print.","author":"Grainger BT, Cheah CY.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39540208"},{"title01":"In T-follicular helper lymphomas, ‘one lymphoma can hide another’: beginning to explain","title02":"In T-follicular helper lymphomas, ‘one lymphoma can hide another’: beginning to explain","journal":"Haematologica","issue":"2024 Nov 14. doi: 10.3324\/haematol.2024.286173. Online ahead of print.","author":"Lemonnier F, Philippe G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39540214"},{"title01":"Dynamics of measurable residual disease for risk stratification and guiding allogeneic transplant in acute myeloid leukaemia patients with myelodysplasia-related mutations in first remission","title02":"Dynamics of measurable residual disease for risk stratification and guiding allogeneic transplant in acute myeloid leukaemia patients with myelodysplasia-related mutations in first remission","journal":"Br J Haematol","issue":"2024 Nov 22. doi: 10.1111\/bjh.19917. Online ahead of print.","author":"Jiang L, Cheng J, Sun J, Zhang Y, Wu Q, Huang Y, Long Z, Yan P, Jiang X.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39578220"},{"title01":"Greater preservation of SARS-CoV-2 neutralising antibody responses following the ChAdOx1-S (AZD1222) vaccine compared with mRNA vaccines in haematopoietic cell transplant recipients","title02":"Greater preservation of SARS-CoV-2 neutralising antibody responses following the ChAdOx1-S (AZD1222) vaccine compared with mRNA vaccines in haematopoietic cell transplant recipients","journal":"Br J Haematol","issue":"2024 Nov 17. doi: 10.1111\/bjh.19874. Online ahead of print.","author":"Colton H, Barratt N, Temperton N, Hornsby H, Angyal A, Grouneva I, Lindsey BB, Kearns P, Barnes E, Goodyear CS, Richter A, Thomas D, Cook G, McInnes IB, Willicombe M, Siebert S, Orchard K, Selby R, Bowden S, Collini PJ, Pope A, Kirkham A, Kronsteiner B, Dunachie SJ, Miller P, Clay J, Hurst E, Malladi R, Kesavan M, Kinsella F, Sanderson R, Yong KL, Rea D, Parry H; PITCH Consortium, OCTAVE Collaborative Group, OCTAVE\u2010DUO Investigators, PROSECO Investigators; Lim SH, Snowden JA, de Silva TI.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39551718"},{"title01":"Itacitinib for Prevention of Graft-Versus-Host Disease and Cytokine Release Syndrome in Haploidentical Transplantation","title02":"Itacitinib for Prevention of Graft-Versus-Host Disease and Cytokine Release Syndrome in Haploidentical Transplantation","journal":"Blood","issue":"2024 Nov 22:blood.2024026497. doi: 10.1182\/blood.2024026497. Online ahead of print.","author":"Abboud R, Schroeder MA, Rettig MP, Jayasinghe RG, Gao F, Eisele J, Gehrs L, Ritchey JK, Choi J, Abboud CN, Pusic I, Jacoby MA, Westervelt P, Christopher M, Cashen AF, Ghobadi A, Stockerl-Goldstein K, Uy GL, DiPersio JF.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39576962"},{"title01":"Ruxolitinib REACHes FOR children with GVHD","title02":"Ruxolitinib REACHes FOR children with GVHD","journal":"Blood","issue":"2024 Nov 14;144(20):2069-2070.","author":"Toubai T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39541105"},{"title01":"Polycomb group protein Mel18 inhibits hematopoietic stem cell self-renewal through repressing the transcription of self-renewal and proliferation genes","title02":"Polycomb group protein Mel18 inhibits hematopoietic stem cell self-renewal through repressing the transcription of self-renewal and proliferation genes","journal":"Leukemia","issue":"2024 Nov 19. doi: 10.1038\/s41375-024-02462-w. Online ahead of print.","author":"Cai W, Liu X, Barajas S, Xiao S, Vemula S, Chen H, Yang Y, Bochers C, Henley D, Liu S, Jia Y, Hong M, Mays TM, Capitano ML, Liu H, Ji P, Gao Z, Pasini D, Wan J, Yue F, Platanias LC, Xi R, Chen S, Liu Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39562720"},{"title01":"Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working parties joint EBMT study","title02":"Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working parties joint EBMT study","journal":"Leukemia","issue":"2024 Nov 19. doi: 10.1038\/s41375-024-02467-5. Online ahead of print.","author":"Ort\u00ed G, Peczynski C, Boreland W, O'Reilly M, von Bonin M, Balduzzi A, Besley C, Kalwak K, Ryh\u00e4nen S, G\u00fcng\u00f6r T, Wynn RF, Bader P, Mielke S, Blaise D, Amrolia P, Yakoub-Agha I, Calkoen F, Schubert ML, Potter V, Pichler H, Kr\u00f6ger N, Kwon M, Sengeloev H, Torrent A, Chalandon Y, van Gorkom G, Koenecke C, Graham C, Schoemans H, Moiseev I, Penack O, Peric Z.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39562721"},{"title01":"Randomized Controlled Trial of a Virtually Delivered Exercise and Stress Management Program to Improve Physical Performance of Hematopoietic Cell Transplant Survivors","title02":"Randomized Controlled Trial of a Virtually Delivered Exercise and Stress Management Program to Improve Physical Performance of Hematopoietic Cell Transplant Survivors","journal":"J Clin Oncol","issue":"2024 Nov 26:JCO2400333. doi: 10.1200\/JCO.24.00333. Online ahead of print.","author":"Ma DD, Liu Z, Au K, Tran M, Artuz CM, Greenwood M, Bilmon I, Kliman D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39591546"},{"title01":"Arkadia: a new player in hematopoietic stem and progenitor cell development","title02":"Arkadia: a new player in hematopoietic stem and progenitor cell development","journal":"Haematologica","issue":"2024 Nov 21. doi: 10.3324\/haematol.2024.286587. Online ahead of print.","author":"Ketharnathan S, Berman JN.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39568415"},{"title01":"Optimization of T-cell replete haploidentical hematopoietic stem cell transplantation: the Chinese experience","title02":"Optimization of T-cell replete haploidentical hematopoietic stem cell transplantation: the Chinese experience","journal":"Haematologica","issue":"2024 Nov 21. doi: 10.3324\/haematol.2024.286194. Online ahead of print.","author":"Mo X, Pei X, Huang X.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39568419"},{"title01":"Greater preservation of SARS-CoV-2 neutralising antibody responses following the ChAdOx1-S (AZD1222) vaccine compared with mRNA vaccines in haematopoietic cell transplant recipients","title02":"Greater preservation of SARS-CoV-2 neutralising antibody responses following the ChAdOx1-S (AZD1222) vaccine compared with mRNA vaccines in haematopoietic cell transplant recipients","journal":"Br J Haematol","issue":"2024 Nov 17. doi: 10.1111\/bjh.19874. Online ahead of print.","author":"Colton H, Barratt N, Temperton N, Hornsby H, Angyal A, Grouneva I, Lindsey BB, Kearns P, Barnes E, Goodyear CS, Richter A, Thomas D, Cook G, McInnes IB, Willicombe M, Siebert S, Orchard K, Selby R, Bowden S, Collini PJ, Pope A, Kirkham A, Kronsteiner B, Dunachie SJ, Miller P, Clay J, Hurst E, Malladi R, Kesavan M, Kinsella F, Sanderson R, Yong KL, Rea D, Parry H; PITCH Consortium, OCTAVE Collaborative Group, OCTAVE\u2010DUO Investigators, PROSECO Investigators; Lim SH, Snowden JA, de Silva TI.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39551718"},{"title01":"Adding eltrombopag to intensive immunosuppressive therapy for severe aplastic anaemia may help adult patients achieve outcomes similar to paediatric patients","title02":"Adding eltrombopag to intensive immunosuppressive therapy for severe aplastic anaemia may help adult patients achieve outcomes similar to paediatric patients","journal":"Leukemia","issue":"2024 Nov 21. doi: 10.1038\/s41375-024-02450-0. Online ahead of print.","author":"Yang B, Wang L, Fu L, Chen M, Ma J, Han B.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39572710"},{"title01":"Comparative study of the diversity of amino acids on human leucocyte antigen class II molecules in patients with acquired aplastic anaemia","title02":"Comparative study of the diversity of amino acids on human leucocyte antigen class II molecules in patients with acquired aplastic anaemia","journal":"Br J Haematol","issue":"2024 Nov 13. doi: 10.1111\/bjh.19899. Online ahead of print.","author":"Qi J, Wang T, Wang M, He P, Li Y, Shang L, Chen L, Wang X, Xu H, Ma C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39538961"},{"title01":"Dissecting the genomic traits and clinical course of secondary myelodysplastic syndrome following aplastic anaemia: A milestone","title02":"Dissecting the genomic traits and clinical course of secondary myelodysplastic syndrome following aplastic anaemia: A milestone","journal":"Br J Haematol","issue":"2024 Nov 14. doi: 10.1111\/bjh.19898. Online ahead of print.","author":"Gurnari C, Visconte V.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39542742"},{"title01":"Pancreatitis-associated thrombotic microangiopathic hematolytic anemia with thrombocytopenia in a child","title02":"Pancreatitis-associated thrombotic microangiopathic hematolytic anemia with thrombocytopenia in a child","journal":"Blood","issue":"2024 Nov 21;144(21):2270.","author":"Kelly C, Kumar R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39570603"},{"title01":"Romiplostim, low-dose rituximab and high-dose dexamethasone for newly diagnosed immune thrombocytopenia: A pilot study","title02":"Romiplostim, low-dose rituximab and high-dose dexamethasone for newly diagnosed immune thrombocytopenia: A pilot study","journal":"Br J Haematol","issue":"2024 Nov 24. doi: 10.1111\/bjh.19923. Online ahead of print.","author":"Colunga-Pedraza PR, De la Garza-Salazar F, Vaquera-Alfaro HA, G\u00f3mez-De Le\u00f3n A, Bustillos-Mu\u00f1oz M, Tar\u00edn-Arzaga L, Cant\u00fa-Rodr\u00edguez O, Guti\u00e9rrez-Aguirre CH, G\u00f3mez-Almaguer D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39581951"},{"title01":"Inhibition of FcRn with rozanolixizumab in adults with immune thrombocytopenia: Two randomised, double-blind, placebo-controlled phase 3 studies and their open-label extension","title02":"Inhibition of FcRn with rozanolixizumab in adults with immune thrombocytopenia: Two randomised, double-blind, placebo-controlled phase 3 studies and their open-label extension","journal":"Br J Haematol","issue":"2024 Nov 18. doi: 10.1111\/bjh.19858. Online ahead of print.","author":"Cooper N, Bussel JB, Ka\u017amierczak M, Miyakawa Y, Cluck S, Lled\u00f3 Garc\u00eda R, Haier B, Lavrov A, Singh P, Snipes R, Kuter DJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39552477"},{"title01":"Let’s YAP about ITP","title02":"Let’s YAP about ITP","journal":"Blood","issue":"2024 Nov 14;144(20):2072-2073.","author":"Kapur R, Semple JW.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39541102"},{"title01":"Clonal hematopoiesis in large granular lymphocytic leukemia","title02":"Clonal hematopoiesis in large granular lymphocytic leukemia","journal":"Leukemia","issue":"2024 Nov 21. doi: 10.1038\/s41375-024-02460-y. Online ahead of print.","author":"Kawashima N, Gurnari C, Bravo-Perez C, Kubota Y, Pagliuca S, Guarnera L, Williams ND, Durmaz A, Ahmed A, Dima D, Ullah F, Carraway HE, Singh A, Visconte V, Maciejewski JP.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39572711"},{"title01":"The co-receptor Neuropilin-1 enhances proliferation in inv(16) acute myeloid leukemia via VEGF signaling","title02":"The co-receptor Neuropilin-1 enhances proliferation in inv(16) acute myeloid leukemia via VEGF signaling","journal":"Leukemia","issue":"2024 Nov 21. doi: 10.1038\/s41375-024-02471-9. Online ahead of print.","author":"Hegde M, Ahmad MH, Mulet Lazaro R, Sugita M, Li R, Hu K, Gebhard C, Guzman ML, Bushweller JH, Zhu LJ, Brehm M, Wolfe SA, Delwel R, Castilla LH.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39572712"},{"title01":"CLL crosstalk with na\u00efve T cells enhances the differentiation of IL-22-producing T cells and CLL -cell survival","title02":"CLL crosstalk with na\u00efve T cells enhances the differentiation of IL-22-producing T cells and CLL -cell survival","journal":"Leukemia","issue":"2024 Nov 22. doi: 10.1038\/s41375-024-02463-9. Online ahead of print.","author":"Ferrer G, Palacios F, Chiu PY, Wong K, Bueno-Costa A, Barrientos JC, Kolitz JE, Allen SL, Rai KR, Chen SS, Sherry B, Chiorazzi N.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39578533"},{"title01":"The glycosyltransferase ST3GAL4 drives immune evasion in acute myeloid leukemia by synthesizing ligands for the glyco-immune checkpoint receptor Siglec-9","title02":"The glycosyltransferase ST3GAL4 drives immune evasion in acute myeloid leukemia by synthesizing ligands for the glyco-immune checkpoint receptor Siglec-9","journal":"Leukemia","issue":"2024 Nov 17. doi: 10.1038\/s41375-024-02454-w. Online ahead of print.","author":"Krishnamoorthy V, Daly J, Kim J, Piatnitca L, Yuen KA, Kumar B, Taherzadeh Ghahfarrokhi M, Bui TQT, Azadi P, Vu LP, Wisnovsky S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39551873"},{"title01":"Glucose uptake capacity of leukaemia cells in vitro correlates with response to induction therapy in acute myeloid leukaemia","title02":"Glucose uptake capacity of leukaemia cells in vitro correlates with response to induction therapy in acute myeloid leukaemia","journal":"Leukemia","issue":"2024 Nov 18. doi: 10.1038\/s41375-024-02469-3. Online ahead of print.","author":"Deng S, Du J, Huang K, Gale RP, Pan D, Wang L, Wei J, Zheng X, Xu Y, Xie S, Zhou W, Xiao W, Liu B, Chen Z, Ju Z, Zeng H.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39558008"},{"title01":"Global patterns of leukemia by subtype, age, and sex in 185 countries in 2022","title02":"Global patterns of leukemia by subtype, age, and sex in 185 countries in 2022","journal":"Leukemia","issue":"2024 Nov 20. doi: 10.1038\/s41375-024-02452-y. Online ahead of print.","author":"Daltveit DS, Morgan E, Colombet M, Steliarova-Foucher E, Bendahhou K, Marcos-Gragera R, Rongshou Z, Smith A, Wei H, Soerjomataram I.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39567675"},{"title01":"Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial","title02":"Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial","journal":"J Clin Oncol","issue":"2024 Nov 27:JCO2400975. doi: 10.1200\/JCO.24.00975. Online ahead of print.","author":"Langerbeins P, Robrecht S, Nieper P, Cramer P, F\u00fcrstenau M, Al-Sawaf O, Simon F, Fink AM, Kreuzer KA, Vehling-Kaiser U, Tausch E, Schneider C, M\u00fcller L, Eckart MJ, Schlag R, Freier W, Gaska T, Balser C, Reiser M, Stauch M, Zahn MO, D\u00f6rfel S, Staib P, Behlendorf T, Hensel M, Hebart H, Klaproth H, Block A, Liersch R, Hauch U, Heinrich B, Wendtner CM, Fischer K, Stilgenbauer S, Eichhorst B, Hallek M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39602678"},{"title01":"Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 Trial","title02":"Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 Trial","journal":"J Clin Oncol","issue":"2024 Nov 18:JCO2400259. doi: 10.1200\/JCO.24.00259. Online ahead of print.","author":"Russell NH, Thomas A, Hills RK, Thomas I, Gilkes A, Almuina NM, Burns S, Marsh L, Vyas P, Metzner M, McCarthy N, Andrew G, Byrne J, Sellar RS, Kelly R, Cahalin P, Overgaard UM, Mehta P, Dennis M, Knapper S, Freeman SD.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39556780"},{"title01":"Short-course subcutaneous alemtuzumab induces clinical responses in relapsed T-cell large granular leukemia","title02":"Short-course subcutaneous alemtuzumab induces clinical responses in relapsed T-cell large granular leukemia","journal":"Haematologica","issue":"2024 Nov 14. doi: 10.3324\/haematol.2024.286235. Online ahead of print.","author":"Ruiz M, Braunstein Z, McLaughlin E, Mishra A, Porcu P, Brammer JE.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39540224"},{"title01":"Is age just a number? Intensive therapy for core binding factor acute myeloid leukemia in older adults","title02":"Is age just a number? Intensive therapy for core binding factor acute myeloid leukemia in older adults","journal":"Haematologica","issue":"2024 Nov 14. doi: 10.3324\/haematol.2024.286640. Online ahead of print.","author":"George BM, Luskin MR.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39540230"},{"title01":"FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome \/ chronic myelomonocytic leukemia receiving CPX-351: a study from the Groupe Francophone des My\u00e9lodysplasies","title02":"FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome \/ chronic myelomonocytic leukemia receiving CPX-351: a study from the Groupe Francophone des My\u00e9lodysplasies","journal":"Haematologica","issue":"2024 Nov 21. doi: 10.3324\/haematol.2024.286025. Online ahead of print.","author":"Peterlin P, Gaschet J, Turlure P, Gourin MP, Dumas PY, Thepot S, Berceanu A, Park S, Hospital MA, Cluzeau T, Torregrosa-Diaz JM, Drevon L, Sapena R, Chermat F, Ades L, Dimicoli-Salazar S, Jullien M, Fenaux P, Chevallier P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39568426"},{"title01":"Acute myeloid leukemia drug tolerant persister cells survive chemotherapy by transiently increasing plasma membrane rigidity, that also increases their sensitivity to immune cell killing","title02":"Acute myeloid leukemia drug tolerant persister cells survive chemotherapy by transiently increasing plasma membrane rigidity, that also increases their sensitivity to immune cell killing","journal":"Haematologica","issue":"2024 Nov 21. doi: 10.3324\/haematol.2024.286018. Online ahead of print.","author":"Morgenstern Y, Lee J, Na Y, Lieng BY, Ly NS, Gwynne WD, Hurren R, Ma L, Ling D, Gronda M, Arruda A, Frisch A, Zuckerman T, Ofran Y, Minden MD, Zhang L, O'Brien C, Quaile AT, Montenegro-Burke JR, Schimmer AD.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39568440"},{"title01":"Better late than never: Delayed asparaginase during induction for acute lymphoblastic leukaemia in adults","title02":"Better late than never: Delayed asparaginase during induction for acute lymphoblastic leukaemia in adults","journal":"Br J Haematol","issue":"2024 Nov 24. doi: 10.1111\/bjh.19928. Online ahead of print.","author":"Valtis YK, Luskin MR.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39582037"},{"title01":"Preclinical activity of resazurin in acute myeloid leukaemia","title02":"Preclinical activity of resazurin in acute myeloid leukaemia","journal":"Br J Haematol","issue":"2024 Nov 24. doi: 10.1111\/bjh.19872. Online ahead of print.","author":"Ha TQ, Andresen V, Erikstein BS, Popa M, Gullaksen SE, Reikvam H, McCormack E, Gjertsen BT.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39582120"},{"title01":"A monstrous relapsed hairy cell leukaemia with large cells","title02":"A monstrous relapsed hairy cell leukaemia with large cells","journal":"Br J Haematol","issue":"2024 Nov 25. doi: 10.1111\/bjh.19911. Online ahead of print.","author":"Paillassa J, Genevieve F, Maitre E, Troussard X.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39587423"},{"title01":"Aggressive NK-cell leukaemia: Diverse morphology, distinct clinical features","title02":"Aggressive NK-cell leukaemia: Diverse morphology, distinct clinical features","journal":"Br J Haematol","issue":"2024 Nov 25. doi: 10.1111\/bjh.19910. Online ahead of print.","author":"Ousset L, Carr\u00e9 L, Protin C, Gadaud N, Evrard S, Rieu JB.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39587425"},{"title01":"Salvage monotherapy with venetoclax after failure from a single course of standard induction chemotherapy for acute myeloid leukaemia","title02":"Salvage monotherapy with venetoclax after failure from a single course of standard induction chemotherapy for acute myeloid leukaemia","journal":"Br J Haematol","issue":"2024 Nov 26. doi: 10.1111\/bjh.19906. Online ahead of print.","author":"Sansen PY, Graux C, Sonet A, Andr\u00e9 M, Doyen C, Collinge E, Vellemans H, Bernard W, Crochet G, Devreux J, Depaus J, Devalet B, Desquesnes F, Pouplard M, Dachy F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39592448"},{"title01":"Chronic eosinophilic leukaemia-Not otherwise specified: Clinical features, genomic insight and therapeutic strategies","title02":"Chronic eosinophilic leukaemia-Not otherwise specified: Clinical features, genomic insight and therapeutic strategies","journal":"Br J Haematol","issue":"2024 Nov 26. doi: 10.1111\/bjh.19921. Online ahead of print.","author":"Costa A, Scalzulli E, Breccia M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39600052"},{"title01":"Measurable residual disease-driven treatment in first-line chronic lymphocytic leukaemia","title02":"Measurable residual disease-driven treatment in first-line chronic lymphocytic leukaemia","journal":"Br J Haematol","issue":"2024 Nov 13. doi: 10.1111\/bjh.19902. Online ahead of print.","author":"Davids MS, Lin KH, Mohamed AI, Munir T, Eyre TA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39538975"},{"title01":"Real-world experience of paediatric acute promyelocytic leukaemia in the United Kingdom and Ireland","title02":"Real-world experience of paediatric acute promyelocytic leukaemia in the United Kingdom and Ireland","journal":"Br J Haematol","issue":"2024 Nov 17. doi: 10.1111\/bjh.19843. Online ahead of print.","author":"Vedi A, Leiter SM, Memon IL, Mahendrayogam A, Van Rijswijk E, Uparkar U, Shenton G, Trinquand A, Clesham K, McLelland V, Campbell H, Patrick K, Thompson L, Baird S, Connor P, Lancaster D, James B.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39551717"},{"title01":"Ven-Aza outcomes in AML by genetic risk","title02":"Ven-Aza outcomes in AML by genetic risk","journal":"Blood","issue":"2024 Nov 21;144(21):2271.","author":"No authors listed","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39570596"},{"title01":"CD70 CAR T cells secreting an anti-CD33\/anti-CD3 dual targeting antibody overcome antigen heterogeneity in AML","title02":"CD70 CAR T cells secreting an anti-CD33\/anti-CD3 dual targeting antibody overcome antigen heterogeneity in AML","journal":"Blood","issue":"2024 Nov 21:blood.2023023210. doi: 10.1182\/blood.2023023210. Online ahead of print.","author":"Silva H, Martin G, Birocchi F, Wehrli M, Kann MC, Supper VM, Parker A, Graham CE, Bratt AG, Bouffard AA, Donner H, Escobar G, Takei HN, Armstrong A, Goncalves S, Berger TR, Choi BD, Maus MV, Leick MB.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39571145"},{"title01":"Approaching a therapeutic inflection point for FLT3-mutated AML","title02":"Approaching a therapeutic inflection point for FLT3-mutated AML","journal":"Blood","issue":"2024 Nov 14:blood.2024024248. doi: 10.1182\/blood.2024024248. Online ahead of print.","author":"Perl AE.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39541573"},{"title01":"Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML","title02":"Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML","journal":"Blood","issue":"2024 Nov 19:blood.2024026388. doi: 10.1182\/blood.2024026388. Online ahead of print.","author":"Fiskus W, Mill CP, Bose P, Masarova L, Pemmaraju N, Dunbar A, Birdwell C, Davis JA, Das K, Hou H, Manshouri T, Jain A, Malovannaya A, Philip K, Alhamadani N, Matthews A, Lin K, Flores L, Loghavi S, DiNardo CD, Su X, Rampal RK, Bhalla KN.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39561280"},{"title01":"Loncastuximab in high-risk and heavily pretreated relapsed \/ refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centers","title02":"Loncastuximab in high-risk and heavily pretreated relapsed \/ refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centers","journal":"Haematologica","issue":"2024 Nov 14:0. doi: 10.3324\/haematol.2024.285977. Online ahead of print.","author":"Zelikson V, Gurumurthi A, Sawalha Y, Annunzio K, Saha A, Dong N, Qualls D, Amoozgar B, Kahl B, Baird J, Challa P, Huntington SF, Santos J, Bair S, Narkhede M, Li S, Frosch Z, Ho C, Smith SD, Winter A, Landsburg D, Furqan F, Hamadani M, Baird K, Romancik J, Alharthy H, Law J, Bojanini L, Advani R, Hu B, Johnson PC, Grover NS, Merril M, Crombie JL, Shafagati N, Sterling C, Nastoupil LJ, Epperla N, Ayers EC.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39540227"},{"title01":"Inequalities in geographic barriers and patient representation in lymphoma clinical trials across England","title02":"Inequalities in geographic barriers and patient representation in lymphoma clinical trials across England","journal":"Br J Haematol","issue":"2024 Nov 27. doi: 10.1111\/bjh.19907. Online ahead of print.","author":"Jones DA, Spencer K, Ramroth J, Probert J, Roope LSJ, Shakir R, Broggio J, Burroughs F, Collins GP, Clarke PM, Wolstenholme JL, Cutter DJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39604053"},{"title01":"Lasalocid A selectively induces the degradation of MYD88 in lymphomas harboring the MYD88 L265P mutation","title02":"Lasalocid A selectively induces the degradation of MYD88 in lymphomas harboring the MYD88 L265P mutation","journal":"Blood","issue":"2024 Nov 22:blood.2024026781. doi: 10.1182\/blood.2024026781. Online ahead of print.","author":"Li W, Wang R, Wang J, Chai D, Xie X, Young KHH, Cao Y, Li Y, Yu X.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39576960"},{"title01":"Building the Future Management of Follicular Lymphoma with T-Cell-Redirecting Strategies","title02":"Building the Future Management of Follicular Lymphoma with T-Cell-Redirecting Strategies","journal":"Blood","issue":"2024 Nov 14:blood.2024025699. doi: 10.1182\/blood.2024025699. Online ahead of print.","author":"Iacoboni G, Morschhauser F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39541577"},{"title01":"Ixazomib, pomalidomide and dexamethasone in relapsed or refractory multiple myeloma characterized with high-risk cytogenetics: the IFM 2014-01 study","title02":"Ixazomib, pomalidomide and dexamethasone in relapsed or refractory multiple myeloma characterized with high-risk cytogenetics: the IFM 2014-01 study","journal":"Haematologica","issue":"2024 Nov 14. doi: 10.3324\/haematol.2024.285916. Online ahead of print.","author":"Bobin A, Manier S, De Keizer J, Srimani JK, Hulin C, Karlin L, Caillot D, Lafon I, Mariette C, Araujo C, Arnulf B, Bareau B, Belhadj K, Benboubker L, Braun T, Calmettes C, Decaux O, Dib M, Demarquette H, Jacquet C, Sonntag C, Godet S, Jaccard A, Lenain P, Macro M, Richez-Olivier V, Tiab M, Vincent L, Zerazhi H, P\u00e9tillon MO, Rollet S, Gardeney H, Durand G, Levy A, Touzeau C, Perrot A, Moreau P, Facon T, Corre J, Ragot S, Avet-Loiseau H, Leleu X.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39540213"},{"title01":"Teclistamab in relapsed refractory multiple myeloma: a multi-institutional real-world study from the French early access program","title02":"Teclistamab in relapsed refractory multiple myeloma: a multi-institutional real-world study from the French early access program","journal":"Haematologica","issue":"2024 Nov 21. doi: 10.3324\/haematol.2024.286118. Online ahead of print.","author":"Perrot A, Hulin C, Boumendil A, Manjra H, Leveque A, Croizier C, Dony A, Mohty M, Roussel M, Manier S, Orsini-Piocelle F, Bauschert L, Bobin A, Frenzel L, Vincent L, Breal C, Eveillard JR, Gerome T, Tiab M, Chalayer E, Belkhir R, Mariette C, Moyer P, Chalopin T, Cherel B, Montes L, Coste A, Tabrizi R, Karlin L, Robu D, Huguet A, Harel S, Moreau P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39568438"},{"title01":"Resistance to immunomodulatory drugs in multiple myeloma: the cereblon pathway and beyond","title02":"Resistance to immunomodulatory drugs in multiple myeloma: the cereblon pathway and beyond","journal":"Haematologica","issue":"2024 Nov 21. doi: 10.3324\/haematol.2024.285636. Online ahead of print.","author":"Teoh PJ, Koh MY, Mitsiades C, Gooding S, Chng WJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39569422"},{"title01":"Dutcher bodies and Russell bodies in a case of t(11;14) multiple myeloma","title02":"Dutcher bodies and Russell bodies in a case of t(11;14) multiple myeloma","journal":"Br J Haematol","issue":"2024 Nov 14. doi: 10.1111\/bjh.19890. Online ahead of print.","author":"Wu J, Cai W, Jiang M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39543449"},{"title01":"M-protein-related necrobiotic granuloma in a multiple myeloma patient treated with daratumumab, lenalidomide and dexamethasone","title02":"M-protein-related necrobiotic granuloma in a multiple myeloma patient treated with daratumumab, lenalidomide and dexamethasone","journal":"Br J Haematol","issue":"2024 Nov 14. doi: 10.1111\/bjh.19887. Online ahead of print.","author":"Bertuglia G, Bringhen S, Bruno B, Impal\u00e0 GA, D'Agostino M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39543460"},{"title01":"Are we there yet? CAR-T therapy in multiple myeloma","title02":"Are we there yet? CAR-T therapy in multiple myeloma","journal":"Br J Haematol","issue":"2024 Nov 19. doi: 10.1111\/bjh.19896. Online ahead of print.","author":"Mirvis E, Benjamin R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39558776"},{"title01":"CD71(+) erythroid cells promote multiple myeloma progression and\u00a0impair anti-bacterial immune response","title02":"CD71(+) erythroid cells promote multiple myeloma progression and\u00a0impair anti-bacterial immune response","journal":"Br J Haematol","issue":"2024 Nov 20. doi: 10.1111\/bjh.19914. Online ahead of print.","author":"Czubak K, Grzywa TM, Sidor-Dzitkowska K, Pilch Z, Bielak K, Hoser G, Gewartowska O, Malecka-Gieldowska M, Barankiewicz J, Garbicz F, Ciepiela O, Juszczynski P, Owczarek A, Wegrzynowicz M, Skirecki T, Golab J, Nowis D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39567409"},{"title01":"Beyond static measurements: dynamic frailty improves survival prediction in multiple myeloma","title02":"Beyond static measurements: dynamic frailty improves survival prediction in multiple myeloma","journal":"Blood","issue":"2024 Nov 22:blood.2024025868. doi: 10.1182\/blood.2024025868. Online ahead of print.","author":"Smits F, Groen K, Levin MD, Stege C, van Kampen RJW, van der Spek E, Bilgin YM, Thielen N, Nijhof IS, Ludwig I, de Waal EGM, Sandberg Y, Kentos A, Timmers GJ, Regelink JC, Westerman M, Heer K, Vekemans MM, Durdu-Rayman N, de Graauw NCHP, Seefat MR, van de Donk NWCJ, Ypma PF, Nasserinejad K, Zweegman S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39576961"},{"title01":"Dimethyl fumarate ameliorates chronic graft-versus-host disease by inhibiting Tfh differentiation via Nrf2","title02":"Dimethyl fumarate ameliorates chronic graft-versus-host disease by inhibiting Tfh differentiation via Nrf2","journal":"Leukemia","issue":"2024 Nov 23. doi: 10.1038\/s41375-024-02475-5. Online ahead of print.","author":"Lyu F, Gong H, Wu X, Liu X, Lu Y, Wei X, Liu C, Shen Y, Wang Y, Lei L, Chen J, Ma S, Sun H, Yu D, Han J, Xu Y, Wu D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39580582"},{"title01":"Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working parties joint EBMT study","title02":"Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working parties joint EBMT study","journal":"Leukemia","issue":"2024 Nov 19. doi: 10.1038\/s41375-024-02467-5. Online ahead of print.","author":"Ort\u00ed G, Peczynski C, Boreland W, O'Reilly M, von Bonin M, Balduzzi A, Besley C, Kalwak K, Ryh\u00e4nen S, G\u00fcng\u00f6r T, Wynn RF, Bader P, Mielke S, Blaise D, Amrolia P, Yakoub-Agha I, Calkoen F, Schubert ML, Potter V, Pichler H, Kr\u00f6ger N, Kwon M, Sengeloev H, Torrent A, Chalandon Y, van Gorkom G, Koenecke C, Graham C, Schoemans H, Moiseev I, Penack O, Peric Z.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39562721"},{"title01":"Randomized Controlled Trial of a Virtually Delivered Exercise and Stress Management Program to Improve Physical Performance of Hematopoietic Cell Transplant Survivors","title02":"Randomized Controlled Trial of a Virtually Delivered Exercise and Stress Management Program to Improve Physical Performance of Hematopoietic Cell Transplant Survivors","journal":"J Clin Oncol","issue":"2024 Nov 26:JCO2400333. doi: 10.1200\/JCO.24.00333. Online ahead of print.","author":"Ma DD, Liu Z, Au K, Tran M, Artuz CM, Greenwood M, Bilmon I, Kliman D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39591546"},{"title01":"Optimization of T-cell replete haploidentical hematopoietic stem cell transplantation: the Chinese experience","title02":"Optimization of T-cell replete haploidentical hematopoietic stem cell transplantation: the Chinese experience","journal":"Haematologica","issue":"2024 Nov 21. doi: 10.3324\/haematol.2024.286194. Online ahead of print.","author":"Mo X, Pei X, Huang X.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39568419"},{"title01":"Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia","title02":"Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia","journal":"N Engl J Med","issue":"2024 Nov 27. doi: 10.1056\/NEJMoa2406526. Online ahead of print.","author":"Roddie C, Sandhu KS, Tholouli E, Logan AC, Shaughnessy P, Barba P, Ghobadi A, Guerreiro M, Yallop D, Abedi M, Pantin JM, Yared JA, Beitinjaneh AM, Chaganti S, Hodby K, Menne T, Arellano ML, Malladi R, Shah BD, Mountjoy L, O'Dwyer KM, Peggs KS, Lao-Sirieix P, Zhang Y, Brugger W, Braendle E, Pule M, Bishop MR, DeAngelo DJ, Park JH, Jabbour E.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39602653"},{"title01":"Dynamics of measurable residual disease for risk stratification and guiding allogeneic transplant in acute myeloid leukaemia patients with myelodysplasia-related mutations in first remission","title02":"Dynamics of measurable residual disease for risk stratification and guiding allogeneic transplant in acute myeloid leukaemia patients with myelodysplasia-related mutations in first remission","journal":"Br J Haematol","issue":"2024 Nov 22. doi: 10.1111\/bjh.19917. Online ahead of print.","author":"Jiang L, Cheng J, Sun J, Zhang Y, Wu Q, Huang Y, Long Z, Yan P, Jiang X.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39578220"},{"title01":"Long-term follow-up of bulky classic Hodgkin lymphoma managed with ABVD and PET-guided RT demonstrates excellent outcomes in PET-negative cases","title02":"Long-term follow-up of bulky classic Hodgkin lymphoma managed with ABVD and PET-guided RT demonstrates excellent outcomes in PET-negative cases","journal":"Br J Haematol","issue":"2024 Nov 7. doi: 10.1111\/bjh.19859. Online ahead of print.","author":"Kim JL, Villa D, Tonseth RP, Gerrie AS, Wilson D, Benard F, Venner CP, Skinnider B, Farinha P, Slack GW, Lo AC, Scott DW, Sehn LH, Savage KJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39511886"},{"title01":"Pembrolizumab as salvage treatment for T-cell\/histiocyte-rich and Epstein-Barr virus-positive large B-cell lymphoma","title02":"Pembrolizumab as salvage treatment for T-cell\/histiocyte-rich and Epstein-Barr virus-positive large B-cell lymphoma","journal":"Br J Haematol","issue":"2024 Nov 13. doi: 10.1111\/bjh.19883. Online ahead of print.","author":"Schena A, Quaglia FM, Parisi A, Ferrarini I, Moioli A, Tagliavini E, Bernardelli A, Visco C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39535342"},{"title01":"Assessment of fitness for bleomycin use and management of bleomycin pulmonary toxicity in patients with classical Hodgkin lymphoma: A British Society for Haematology Good Practice Paper","title02":"Assessment of fitness for bleomycin use and management of bleomycin pulmonary toxicity in patients with classical Hodgkin lymphoma: A British Society for Haematology Good Practice Paper","journal":"Br J Haematol","issue":"2024 Nov 6. doi: 10.1111\/bjh.19840. Online ahead of print.","author":"Barrett A, Shah N, Chadwick A, Burns D, Burton C, Cutter DJ, Follows GA, McKay P, Osborne W, Phillips E, Wilson MR, Collins GP.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39506502"},{"title01":"Chronic hepatitis E in a patient after chimeric antigen receptor-T-cell treatment for diffuse large B-cell lymphoma and rapid progression towards decompensated liver cirrhosis","title02":"Chronic hepatitis E in a patient after chimeric antigen receptor-T-cell treatment for diffuse large B-cell lymphoma and rapid progression towards decompensated liver cirrhosis","journal":"Br J Haematol","issue":"2024 Nov 7. doi: 10.1111\/bjh.19892. Online ahead of print.","author":"Schwarz M, Mozayani B, Trauner M, St\u00e4ttermayer AF.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39506930"},{"title01":"B-cell acute lymphoblastic leukemia with MEF2D::BCL9 rearrangement mimicking a Burkitt lymphoma","title02":"B-cell acute lymphoblastic leukemia with MEF2D::BCL9<\/i> rearrangement mimicking a Burkitt lymphoma","journal":"Blood","issue":"2024 Nov 7;144(19):2067.","author":"Chevalier S, Legrand C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39509118"},{"title01":"Relevance of the E756del common variant in the PIEZO1 gene for haemolytic anaemia and hepatic iron overload","title02":"Relevance of the E756del common variant in the PIEZO1<\/i> gene for haemolytic anaemia and hepatic iron overload","journal":"Br J Haematol","issue":"2024 Nov 6. doi: 10.1111\/bjh.19886. Online ahead of print.","author":"Esposito FM, D'Onofrio V, Rosato BE, Marra R, Nostroso A, Iscaro A, Manno M, Ribersani M, Giorgi V, Celia R, Piscopo C, Iolascon A, Russo R, Andolfo I.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39506503"},{"title01":"Relevance of the E756del common variant in the PIEZO1 gene for haemolytic anaemia and hepatic iron overload","title02":"Relevance of the E756del common variant in the PIEZO1<\/i> gene for haemolytic anaemia and hepatic iron overload","journal":"Br J Haematol","issue":"2024 Nov 6. doi: 10.1111\/bjh.19886. Online ahead of print.","author":"Esposito FM, D'Onofrio V, Rosato BE, Marra R, Nostroso A, Iscaro A, Manno M, Ribersani M, Giorgi V, Celia R, Piscopo C, Iolascon A, Russo R, Andolfo I.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39506503"},{"title01":"Revumenib Revises the Treatment Landscape for KMT2A-r Leukemia","title02":"Revumenib Revises the Treatment Landscape for KMT2A<\/i>-r Leukemia","journal":"J Clin Oncol","issue":"2024 Nov 7:JCO2401265. doi: 10.1200\/JCO-24-01265. Online ahead of print.","author":"Heikamp EB, Armstrong SA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39509656"},{"title01":"B-cell acute lymphoblastic leukemia with MEF2D::BCL9 rearrangement mimicking a Burkitt lymphoma","title02":"B-cell acute lymphoblastic leukemia with MEF2D::BCL9<\/i> rearrangement mimicking a Burkitt lymphoma","journal":"Blood","issue":"2024 Nov 7;144(19):2067.","author":"Chevalier S, Legrand C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39509118"},{"title01":"Importance of predicting CML therapy failure","title02":"Importance of predicting CML therapy failure","journal":"Blood","issue":"2024 Oct 31;144(18):1852-1853.","author":"Saglio G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39480416"},{"title01":"Long-term Outcomes of tyrosine kinase inhibitors in chronic myeloid leukemia","title02":"Long-term Outcomes of tyrosine kinase inhibitors in chronic myeloid leukemia","journal":"Blood","issue":"2024 Nov 1:blood.2024026311. doi: 10.1182\/blood.2024026311. Online ahead of print.","author":"Guilhot F, Hehlmann R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39486043"},{"title01":"Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML","title02":"Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML","journal":"Blood","issue":"2024 Nov 1:blood.2024026925. doi: 10.1182\/blood.2024026925. Online ahead of print.","author":"Lachowiez CA, Ravikumar VI, Othman J, O'Nions J, Peters DT, McMahon C, Swords R, Cook R, Saultz JN, Tyner JW, Dillon RJ, Zeidner JF, Pollyea DA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39486083"},{"title01":"Acute Promyelocytic Leukemia: Long-Term Outcomes from the HARMONY Project","title02":"Acute Promyelocytic Leukemia: Long-Term Outcomes from the HARMONY Project","journal":"Blood","issue":"2024 Nov 6:blood.2024026186. doi: 10.1182\/blood.2024026186. Online ahead of print.","author":"Voso MT, Guarnera L, Lehmann S, D\u00f6hner K, D\u00f6hner H, Platzbecker U, Russell NH, Dillon RJ, Thomas I, Ossenkoppele GJ, Haferlach T, Vignetti M, La Sala E, Piciocchi A, Fazi P, Villaverde Ramiro \u00c1, Tur Gim\u00e9nez L, Gurnari C, Bullinger L, Hernandez JM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39504485"},{"title01":"Valemetostat monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma: a first-in-human, multicentre, open-label, single-arm, phase 1 study","title02":"Valemetostat monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma: a first-in-human, multicentre, open-label, single-arm, phase 1 study","journal":"Lancet Oncol","issue":"2024 Oct 29:S1470-2045(24)00502-3. doi: 10.1016\/S1470-2045(24)00502-3. Online ahead of print.","author":"Maruyama D, Jacobsen E, Porcu P, Allen P, Ishitsuka K, Kusumoto S, Narita T, Tobinai K, Foss F, Tsukasaki K, Feldman T, Imaizumi Y, Izutsu K, Morishima S, Yamauchi N, Yuda J, Brammer JE, Kawamata T, Ruan J, Nosaka K, Utsunomiya A, Wang J, Zain J, Kakurai Y, Yamauchi H, Hizukuri Y, Biserna N, Tachibana M, Inoue A, Horwitz SM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39486432"},{"title01":"Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study","title02":"Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study","journal":"Lancet Oncol","issue":"2024 Oct 29:S1470-2045(24)00503-5. doi: 10.1016\/S1470-2045(24)00503-5. Online ahead of print.","author":"Zinzani PL, Izutsu K, Mehta-Shah N, Barta SK, Ishitsuka K, C\u00f3rdoba R, Kusumoto S, Bachy E, Cwynarski K, Gritti G, Prica A, Jacobsen E, Feldman T, Guillermin Y, Ennishi D, Yoon DH, Domenech ED, Zain J, Wang J, Kim JS, Poel MV, Jin J, Wu S, Chen Y, Moriyama T, Inoue A, Nakajima K, Horwitz SM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39486433"},{"title01":"Intravascular large B-cell lymphoma presenting with non-occlusive mesenteric ischaemia","title02":"Intravascular large B-cell lymphoma presenting with non-occlusive mesenteric ischaemia","journal":"Lancet","issue":"2024 Nov 9;404(10465):e5.","author":"Nakamura K, Inoue T, Takada A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39521516"},{"title01":"Assessment of fitness for bleomycin use and management of bleomycin pulmonary toxicity in patients with classical Hodgkin lymphoma: A British Society for Haematology Good Practice Paper","title02":"Assessment of fitness for bleomycin use and management of bleomycin pulmonary toxicity in patients with classical Hodgkin lymphoma: A British Society for Haematology Good Practice Paper","journal":"Br J Haematol","issue":"2024 Nov 6. doi: 10.1111\/bjh.19840. Online ahead of print.","author":"Barrett A, Shah N, Chadwick A, Burns D, Burton C, Cutter DJ, Follows GA, McKay P, Osborne W, Phillips E, Wilson MR, Collins GP.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39506502"},{"title01":"Chronic hepatitis E in a patient after chimeric antigen receptor-T-cell treatment for diffuse large B-cell lymphoma and rapid progression towards decompensated liver cirrhosis","title02":"Chronic hepatitis E in a patient after chimeric antigen receptor-T-cell treatment for diffuse large B-cell lymphoma and rapid progression towards decompensated liver cirrhosis","journal":"Br J Haematol","issue":"2024 Nov 7. doi: 10.1111\/bjh.19892. Online ahead of print.","author":"Schwarz M, Mozayani B, Trauner M, St\u00e4ttermayer AF.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39506930"},{"title01":"Introduction to a review series on peripheral T-cell lymphomas: salutary complexity?","title02":"Introduction to a review series on peripheral T-cell lymphomas: salutary complexity?","journal":"Blood","issue":"2024 Oct 31;144(18):1847-1848.","author":"Armand P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39480415"},{"title01":"Comparison of EasyM, a clonotypic mass spectrometry assay, and EuroFlow minimal residual disease assessment in multiple myeloma","title02":"Comparison of EasyM, a clonotypic mass spectrometry assay, and EuroFlow minimal residual disease assessment in multiple myeloma","journal":"Haematologica","issue":"2024 Nov 7. doi: 10.3324\/haematol.2024.285933. Online ahead of print.","author":"Zhao J, Khong T, Gorniak M, Khaled A, McDonald Z, Reynolds J, Mithraprabhu S, Bingham N, Lim S, Wong D, Johnston A, Motorna O, Murphy N, Quach H, Yang L, Spencer A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39506908"},{"title01":"Lung Transplantation","title02":"Lung Transplantation","journal":"N Engl J Med","issue":"2024 Nov 14;391(19):1822-1836.","author":"Christie JD, Van Raemdonck D, Fisher AJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39536228"},{"title01":"Post-transplant cyclophosphamide separates graft-versus host disease and graft versus leukemia effects after HLA-matched stem-cell transplantation for acute myeloid leukemia","title02":"Post-transplant cyclophosphamide separates graft-versus host disease and graft versus leukemia effects after HLA-matched stem-cell transplantation for acute myeloid leukemia","journal":"Leukemia","issue":"2024 Oct 31. doi: 10.1038\/s41375-024-02445-x. Online ahead of print.","author":"Shimoni A, Peczynski C, Labopin M, Kulagin A, Meijer E, Cornelissen J, Choi G, Sanz J, Rovira M, Van Gorkom G, Kr\u00f6ger N, Koc Y, Vydra J, Diez-Martin JL, Solano C, Patel A, Chiusolo P, Ciceri F, Nagler A, Mohty M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39482353"},{"title01":"Haematopoietic stem-cell transplantation for sickle cell disease in low-income and middle-income countries: the experience in India","title02":"Haematopoietic stem-cell transplantation for sickle cell disease in low-income and middle-income countries: the experience in India","journal":"Lancet Haematol","issue":"2024 Nov;11(11):e812-e813.","author":"Gupta V, Krishnamurti L.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39482019"},{"title01":"Induced pluripotent stem-cell-derived corneal epithelium for transplant surgery: a single-arm, open-label, first-in-human interventional study in Japan","title02":"Induced pluripotent stem-cell-derived corneal epithelium for transplant surgery: a single-arm, open-label, first-in-human interventional study in Japan","journal":"Lancet","issue":"2024 Nov 16;404(10466):1929-1939.","author":"Soma T, Oie Y, Takayanagi H, Matsubara S, Yamada T, Nomura M, Yoshinaga Y, Maruyama K, Watanabe A, Takashima K, Mao Z, Quantock AJ, Hayashi R, Nishida K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39522528"},{"title01":"Reply to: Disparities in Allograft Access in the Era of Post-Transplant Cyclophosphamide-Based Mismatched Unrelated Donor Transplantation","title02":"Reply to: Disparities in Allograft Access in the Era of Post-Transplant Cyclophosphamide-Based Mismatched Unrelated Donor Transplantation","journal":"J Clin Oncol","issue":"2024 Nov 6:JCO2402108. doi: 10.1200\/JCO-24-02108. Online ahead of print.","author":"Shaffer BC, Gooptu M, DeFor T, Spellman SR, Stefanski HE, Shaw BE, Auletta JJ, Devine SM, Jimenez AM, Al Malki MM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39504503"},{"title01":"Disparities in Allograft Access in the Era of Post-Transplant Cyclophosphamide-Based Mismatched Unrelated Donor Transplantation","title02":"Disparities in Allograft Access in the Era of Post-Transplant Cyclophosphamide-Based Mismatched Unrelated Donor Transplantation","journal":"J Clin Oncol","issue":"2024 Nov 6:JCO2401824. doi: 10.1200\/JCO-24-01824. Online ahead of print.","author":"Fingrut WB, Scaradavou A, Barker JN.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39504506"},{"title01":"Long-term tracking of haematopoietic clonal dynamics and mutations in non-human primate undergoing transplantation of lentivirally barcoded haematopoietic stem and progenitor cells","title02":"Long-term tracking of haematopoietic clonal dynamics and mutations in non-human primate undergoing transplantation of lentivirally barcoded haematopoietic stem and progenitor cells","journal":"Br J Haematol","issue":"2024 Nov 10. doi: 10.1111\/bjh.19889. Online ahead of print.","author":"Hosuru RV, Yang J, Zhou Y, Gin A, Hayal TB, Hong SG, Dunbar CE, Wu C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39523608"},{"title01":"Post-transplant cyclophosphamide separates graft-versus host disease and graft versus leukemia effects after HLA-matched stem-cell transplantation for acute myeloid leukemia","title02":"Post-transplant cyclophosphamide separates graft-versus host disease and graft versus leukemia effects after HLA-matched stem-cell transplantation for acute myeloid leukemia","journal":"Leukemia","issue":"2024 Oct 31. doi: 10.1038\/s41375-024-02445-x. Online ahead of print.","author":"Shimoni A, Peczynski C, Labopin M, Kulagin A, Meijer E, Cornelissen J, Choi G, Sanz J, Rovira M, Van Gorkom G, Kr\u00f6ger N, Koc Y, Vydra J, Diez-Martin JL, Solano C, Patel A, Chiusolo P, Ciceri F, Nagler A, Mohty M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39482353"},{"title01":"Haematopoietic stem-cell transplantation for sickle cell disease in low-income and middle-income countries: the experience in India","title02":"Haematopoietic stem-cell transplantation for sickle cell disease in low-income and middle-income countries: the experience in India","journal":"Lancet Haematol","issue":"2024 Nov;11(11):e812-e813.","author":"Gupta V, Krishnamurti L.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39482019"},{"title01":"Induced pluripotent stem-cell-derived corneal epithelium for transplant surgery: a single-arm, open-label, first-in-human interventional study in Japan","title02":"Induced pluripotent stem-cell-derived corneal epithelium for transplant surgery: a single-arm, open-label, first-in-human interventional study in Japan","journal":"Lancet","issue":"2024 Nov 16;404(10466):1929-1939.","author":"Soma T, Oie Y, Takayanagi H, Matsubara S, Yamada T, Nomura M, Yoshinaga Y, Maruyama K, Watanabe A, Takashima K, Mao Z, Quantock AJ, Hayashi R, Nishida K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39522528"},{"title01":"Paediatric bone marrow mesenchymal stem cells support acute myeloid leukaemia cell survival and enhance chemoresistance via contact-independent mechanism","title02":"Paediatric bone marrow mesenchymal stem cells support acute myeloid leukaemia cell survival and enhance chemoresistance via contact-independent mechanism","journal":"Br J Haematol","issue":"2024 Nov 10. doi: 10.1111\/bjh.19884. Online ahead of print.","author":"Laing A, Elmarghany A, Alghaith AA, Gouma A, Stevens T, Winton A, Cassels J, Clarke CJ, Schwab C, Harrison CJ, Gibson B, Keeshan K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39523592"},{"title01":"Long-term tracking of haematopoietic clonal dynamics and mutations in non-human primate undergoing transplantation of lentivirally barcoded haematopoietic stem and progenitor cells","title02":"Long-term tracking of haematopoietic clonal dynamics and mutations in non-human primate undergoing transplantation of lentivirally barcoded haematopoietic stem and progenitor cells","journal":"Br J Haematol","issue":"2024 Nov 10. doi: 10.1111\/bjh.19889. Online ahead of print.","author":"Hosuru RV, Yang J, Zhou Y, Gin A, Hayal TB, Hong SG, Dunbar CE, Wu C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39523608"},{"title01":"Safety and efficacy of pegcetacoplan treatment for cold agglutinin disease and warm antibody autoimmune hemolytic anemia","title02":"Safety and efficacy of pegcetacoplan treatment for cold agglutinin disease and warm antibody autoimmune hemolytic anemia","journal":"Blood","issue":"2024 Nov 1:blood.2023022549. doi: 10.1182\/blood.2023022549. Online ahead of print.","author":"Roman E, Fattizzo B, Shum MK, Hanna WT, Lentz SR, Araujo SSS, Al-Adhami M, Grossi FV, Gertz MA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39486046"},{"title01":"Feasibility of plasma proteomics in patients with immune thrombocytopenia","title02":"Feasibility of plasma proteomics in patients with immune thrombocytopenia","journal":"Br J Haematol","issue":"2024 Nov 5. doi: 10.1111\/bjh.19882. Online ahead of print.","author":"Kapur R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39497596"},{"title01":"Endothelial heterogeneity in bone marrow: insights across development, adult life and leukemia","title02":"Endothelial heterogeneity in bone marrow: insights across development, adult life and leukemia","journal":"Leukemia","issue":"2024 Nov 11. doi: 10.1038\/s41375-024-02453-x. Online ahead of print.","author":"Boueya IL, Sandhow L, Albuquerque JRP, Znaidi R, Passaro D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39528790"},{"title01":"Venetoclax in combination with hypomethylating agents in chronic myelomonocytic leukemia: a propensity score matched multicenter cohort study","title02":"Venetoclax in combination with hypomethylating agents in chronic myelomonocytic leukemia: a propensity score matched multicenter cohort study","journal":"Leukemia","issue":"2024 Nov 12. doi: 10.1038\/s41375-024-02466-6. Online ahead of print.","author":"Tremblay D, Csizmar C, DiNardo CD, Ball S, Rippel N, Hammond D, Kadia TM, Ravandi F, Chien K, Van Hyfte G, Mazumdar M, Saliba A, Mangaonkar A, Lasho T, Al-Kali A, Kremyanskaya M, Feld J, Silverman LR, Komrokji R, Mascarenhas J, Padron E, Garcia-Manero G, Sallman DA, Patnaik MM, Montalban-Bravo G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39533069"},{"title01":"Post-transplant cyclophosphamide separates graft-versus host disease and graft versus leukemia effects after HLA-matched stem-cell transplantation for acute myeloid leukemia","title02":"Post-transplant cyclophosphamide separates graft-versus host disease and graft versus leukemia effects after HLA-matched stem-cell transplantation for acute myeloid leukemia","journal":"Leukemia","issue":"2024 Oct 31. doi: 10.1038\/s41375-024-02445-x. Online ahead of print.","author":"Shimoni A, Peczynski C, Labopin M, Kulagin A, Meijer E, Cornelissen J, Choi G, Sanz J, Rovira M, Van Gorkom G, Kr\u00f6ger N, Koc Y, Vydra J, Diez-Martin JL, Solano C, Patel A, Chiusolo P, Ciceri F, Nagler A, Mohty M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39482353"},{"title01":"Transcriptional regulatory program controlled by MYB in T-cell acute lymphoblastic leukemia","title02":"Transcriptional regulatory program controlled by MYB in T-cell acute lymphoblastic leukemia","journal":"Leukemia","issue":"2024 Nov 2. doi: 10.1038\/s41375-024-02455-9. Online ahead of print.","author":"Shao X, Yokomori R, Ong JZL, Shen H, Kappei D, Chen L, Yeoh AEJ, Tan SH, Sanda T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39488662"},{"title01":"Pre-emptive therapeutic decisions based on measurable residual disease status in acute myeloid leukemia: ready for prime time?","title02":"Pre-emptive therapeutic decisions based on measurable residual disease status in acute myeloid leukemia: ready for prime time?","journal":"Leukemia","issue":"2024 Nov 5. doi: 10.1038\/s41375-024-02458-6. Online ahead of print.","author":"El Chaer F, Perissinotti AJ, Loghavi S, Zeidan AM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39496917"},{"title01":"YTHDC1 is a therapeutic target for B-cell acute lymphoblastic leukemia by attenuating DNA damage response through the KMT2C-H3K4me1\/me3 epigenetic axis","title02":"YTHDC1 is a therapeutic target for B-cell acute lymphoblastic leukemia by attenuating DNA damage response through the KMT2C-H3K4me1\/me3 epigenetic axis","journal":"Leukemia","issue":"2024 Nov 5. doi: 10.1038\/s41375-024-02451-z. Online ahead of print.","author":"Li X, Zheng M, Ma S, Nie F, Yin Z, Liang Y, Yan X, Wen W, Yu J, Liang Y, Huang S, Han H.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39501105"},{"title01":"Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance","title02":"Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance","journal":"Haematologica","issue":"2024 Nov 7. doi: 10.3324\/haematol.2024.285805. Online ahead of print.","author":"Sobas MA, Turki AT, Ramiro AV, S\u00e1nchez AH, Elicegui JM, Gonz\u00e1lez T, Melchor RA, Ab\u00e1igar M, Tur L, Dall'Olio D, Str\u00e4ng E, Tettero JM, Castellani G, Benner A, D\u00f6hner K, Thiede C, Metzeler KH, Haferlach T, Damm F, Ayala R, Mart\u00ednez-L\u00f3pez J, Mills KI, Sierra J, Lehmann S, Porta MGD, Mayer J, Reinhardt D, Medina RV, Schulze-Rath R, Barbus M, Hern\u00e1ndez-Rivas JM, Huntly BJP, Ossenkoppele G, D\u00f6hner H, Bullinger L.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39506894"},{"title01":"Venetoclax in combination with a pediatric-inspired regimen for the treatment of newly diagnosed adults with Philadelphia chromosome-negative acute lymphoblastic leukemia","title02":"Venetoclax in combination with a pediatric-inspired regimen for the treatment of newly diagnosed adults with Philadelphia chromosome-negative acute lymphoblastic leukemia","journal":"Haematologica","issue":"2024 Nov 7. doi: 10.3324\/haematol.2024.286427. Online ahead of print.","author":"Aldoss I, Zhang J, Shimamoto K, Saygin C, Robbins M, Agrawal V, Aribi A, Karaoglu DA, Pourhassan H, Koller P, Ali H, Blackmon A, Otoukesh S, Sandhu K, Ball B, Artz AS, Al Malki MM, Salhotra A, Tinajero J, Gu Z, Lagman I, Velasquez M, Dang J, Becker PS, Afkhami M, Ghoda L, Stock W, Forman SJ, Stein A, Marcucci G, Pullarkat V.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39506897"},{"title01":"Arsenic trioxide versus Realgar-Indigo naturalis formula in non-high-risk acute promyelocytic leukemia: a multicenter, randomized trial","title02":"Arsenic trioxide versus Realgar-Indigo naturalis formula in non-high-risk acute promyelocytic leukemia: a multicenter, randomized trial","journal":"Haematologica","issue":"2024 Nov 7. doi: 10.3324\/haematol.2024.285905. Online ahead of print.","author":"Chen S, Qin W, Lu X, Liu L, Zheng Y, Lu X, Wang X, Zhang X, Gong S, Wei S, Zhang H, Ding H, Seifollah R, Li J, Zhang H, Wu D, Abiona O, He P, Zhang R, Wald D, Wang H.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39506905"},{"title01":"Cumulative review of hypertension in patients with chronic lymphocytic leukemia treated with acalabrutinib","title02":"Cumulative review of hypertension in patients with chronic lymphocytic leukemia treated with acalabrutinib","journal":"Haematologica","issue":"2024 Nov 7. doi: 10.3324\/haematol.2024.285757. Online ahead of print.","author":"Ferrajoli A, Follows G, Marmor Y, Roos J, Bajwa N, Madhira V, Nozaki K, Miranda P, Pennap D, Patel K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39506916"},{"title01":"Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance","title02":"Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance","journal":"Haematologica","issue":"2024 Nov 7. doi: 10.3324\/haematol.2024.285805. Online ahead of print.","author":"Sobas MA, Turki AT, Ramiro AV, S\u00e1nchez AH, Elicegui JM, Gonz\u00e1lez T, Melchor RA, Ab\u00e1igar M, Tur L, Dall'Olio D, Str\u00e4ng E, Tettero JM, Castellani G, Benner A, D\u00f6hner K, Thiede C, Metzeler KH, Haferlach T, Damm F, Ayala R, Mart\u00ednez-L\u00f3pez J, Mills KI, Sierra J, Lehmann S, Porta MGD, Mayer J, Reinhardt D, Medina RV, Schulze-Rath R, Barbus M, Hern\u00e1ndez-Rivas JM, Huntly BJP, Ossenkoppele G, D\u00f6hner H, Bullinger L.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39506894"},{"title01":"Venetoclax in combination with a pediatric-inspired regimen for the treatment of newly diagnosed adults with Philadelphia chromosome-negative acute lymphoblastic leukemia","title02":"Venetoclax in combination with a pediatric-inspired regimen for the treatment of newly diagnosed adults with Philadelphia chromosome-negative acute lymphoblastic leukemia","journal":"Haematologica","issue":"2024 Nov 7. doi: 10.3324\/haematol.2024.286427. Online ahead of print.","author":"Aldoss I, Zhang J, Shimamoto K, Saygin C, Robbins M, Agrawal V, Aribi A, Karaoglu DA, Pourhassan H, Koller P, Ali H, Blackmon A, Otoukesh S, Sandhu K, Ball B, Artz AS, Al Malki MM, Salhotra A, Tinajero J, Gu Z, Lagman I, Velasquez M, Dang J, Becker PS, Afkhami M, Ghoda L, Stock W, Forman SJ, Stein A, Marcucci G, Pullarkat V.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39506897"},{"title01":"Arsenic trioxide versus Realgar-Indigo naturalis formula in non-high-risk acute promyelocytic leukemia: a multicenter, randomized trial","title02":"Arsenic trioxide versus Realgar-Indigo naturalis formula in non-high-risk acute promyelocytic leukemia: a multicenter, randomized trial","journal":"Haematologica","issue":"2024 Nov 7. doi: 10.3324\/haematol.2024.285905. Online ahead of print.","author":"Chen S, Qin W, Lu X, Liu L, Zheng Y, Lu X, Wang X, Zhang X, Gong S, Wei S, Zhang H, Ding H, Seifollah R, Li J, Zhang H, Wu D, Abiona O, He P, Zhang R, Wald D, Wang H.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39506905"},{"title01":"Cumulative review of hypertension in patients with chronic lymphocytic leukemia treated with acalabrutinib","title02":"Cumulative review of hypertension in patients with chronic lymphocytic leukemia treated with acalabrutinib","journal":"Haematologica","issue":"2024 Nov 7. doi: 10.3324\/haematol.2024.285757. Online ahead of print.","author":"Ferrajoli A, Follows G, Marmor Y, Roos J, Bajwa N, Madhira V, Nozaki K, Miranda P, Pennap D, Patel K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39506916"},{"title01":"Clinical outcomes in patients in any phase of CML treated with ponatinib in France-Data from the TOPASE observational study","title02":"Clinical outcomes in patients in any phase of CML treated with ponatinib in France-Data from the TOPASE observational study","journal":"Br J Haematol","issue":"2024 Nov 6. doi: 10.1111\/bjh.19819. Online ahead of print.","author":"Huguet F, Guerci-Bresler A, Roth-Guepin G, Cayssials E, Slama B, Santagostino A, Penot A, Quittet P, Cony-Makhoul P, Saad A, Bastie JN, Hacini M, Coiteux V, Uzunov M, Roy L, Le Clech L, Berger M, Agneray AM, Messas E, Etienne G, Turhan A, Nicolini FE, Rousselot P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39506529"},{"title01":"Hydroxy-wybutosine tRNA modifications as indicators of disease progression and therapeutic targets in leukaemia","title02":"Hydroxy-wybutosine tRNA modifications as indicators of disease progression and therapeutic targets in leukaemia","journal":"Br J Haematol","issue":"2024 Nov 10. doi: 10.1111\/bjh.19873. Online ahead of print.","author":"Chen X, Gong RZ, Mo LY, Cheng YT, Ma Y, Qi YT, Yan TM, Jiang ZH.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39523586"},{"title01":"Paediatric bone marrow mesenchymal stem cells support acute myeloid leukaemia cell survival and enhance chemoresistance via contact-independent mechanism","title02":"Paediatric bone marrow mesenchymal stem cells support acute myeloid leukaemia cell survival and enhance chemoresistance via contact-independent mechanism","journal":"Br J Haematol","issue":"2024 Nov 10. doi: 10.1111\/bjh.19884. Online ahead of print.","author":"Laing A, Elmarghany A, Alghaith AA, Gouma A, Stevens T, Winton A, Cassels J, Clarke CJ, Schwab C, Harrison CJ, Gibson B, Keeshan K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39523592"},{"title01":"Targeting RNA modifications in leukaemia: Epitranscriptomic drugs are the new kids on the block","title02":"Targeting RNA modifications in leukaemia: Epitranscriptomic drugs are the new kids on the block","journal":"Br J Haematol","issue":"2024 Nov 10. doi: 10.1111\/bjh.19894. Online ahead of print.","author":"Esteller M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39523653"},{"title01":"Minimal residual disease detection for acute lymphoblastic leukaemia in peripheral blood-Are we there yet?","title02":"Minimal residual disease detection for acute lymphoblastic leukaemia in peripheral blood-Are we there yet?","journal":"Br J Haematol","issue":"2024 Nov 11. doi: 10.1111\/bjh.19888. Online ahead of print.","author":"Trka J, Fronkova E.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39529365"},{"title01":"Delaying pegaspargase during induction in adults with acute lymphoblastic leukaemia is associated with lower risk of high-grade hepatotoxicity without adversely impacting outcomes","title02":"Delaying pegaspargase during induction in adults with acute lymphoblastic leukaemia is associated with lower risk of high-grade hepatotoxicity without adversely impacting outcomes","journal":"Br J Haematol","issue":"2024 Nov 6. doi: 10.1111\/bjh.19880. Online ahead of print.","author":"Tinajero J, Xu S, Ngo D, Li S, Palmer J, Nguyen T, Stein A, Koller P, Agrawal V, Pourhassan H, Murphy L, Forman S, Douer D, Marcucci G, Pullarkat V, Aldoss I.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39505575"},{"title01":"Clinical outcomes in patients in any phase of CML treated with ponatinib in France-Data from the TOPASE observational study","title02":"Clinical outcomes in patients in any phase of CML treated with ponatinib in France-Data from the TOPASE observational study","journal":"Br J Haematol","issue":"2024 Nov 6. doi: 10.1111\/bjh.19819. Online ahead of print.","author":"Huguet F, Guerci-Bresler A, Roth-Guepin G, Cayssials E, Slama B, Santagostino A, Penot A, Quittet P, Cony-Makhoul P, Saad A, Bastie JN, Hacini M, Coiteux V, Uzunov M, Roy L, Le Clech L, Berger M, Agneray AM, Messas E, Etienne G, Turhan A, Nicolini FE, Rousselot P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39506529"},{"title01":"Perspectives on drug development in chronic myelomonocytic leukemia: changing the paradigm","title02":"Perspectives on drug development in chronic myelomonocytic leukemia: changing the paradigm","journal":"Blood","issue":"2024 Nov 7;144(19):1987-1992.","author":"Hunter AM, Patnaik MM, Itzykson R, Mesa R, Karanes C, Li Y, de Claro RA, Norsworthy KJ, Theoret M, Pulte E, Padron E.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39509115"},{"title01":"Toward a new paradigm for CLL treatment","title02":"Toward a new paradigm for CLL treatment","journal":"Blood","issue":"2024 Oct 31;144(18):1849-1850.","author":"Deaglio S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39480414"}]